1
|
Mazevet M, Oberli C, Marinelli S, Zaed I, Bauer S, Kaelin-Lang A, Marchi F, Gardenghi R, Reinert M, Cardia A. Automated online safety margin (GLIOVIS) for glioma surgery model. Front Oncol 2024; 14:1361022. [PMID: 38741783 PMCID: PMC11089175 DOI: 10.3389/fonc.2024.1361022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2023] [Accepted: 04/04/2024] [Indexed: 05/16/2024] Open
Abstract
Purpose Glioblastoma is the most common type of primary brain malignancy and has a poor prognosis. The standard treatment strategy is based on maximal safe surgical resection followed by radiotherapy and chemotherapy. Surgical resection can be optimized by using 5-delta-aminolevulinic acid (5-ALA)-induced fluorescence, which is the current mainstay. Although 5-ALA-induced fluorescence has gained general acceptance, it is also limited by inter-observer variability and non-standardized fluorescence parameters. We present a new software for processing images analysis to better recognize the tumor infiltration margins using an intraoperative immediate safety map of 5-ALA-induced fluorescence. We tested this in a brain model using a commercial surgical exoscope. Methods A dedicated software GLIOVIS (ACQuF-II, Advanced Colorimetry-based Quantification of Fluorescence) was designed for processing analysis of images taken on the Intraoperative Orbital Camera Olympus Orbeye (IOC) to determine the relative quantification of Protoporphyrin IX (5-ALA metabolite) fluorescence. The software allows to superpose the new fluorescence intensity map and the safety margins over the original images. The software was tested on gel-based brain models. Results Two surrogate models were developed: PpIX agarose gel-integrated in gelatin-based brain model at different scales (1:25 and 1:1). The images taken with the IOC were then processed using GLIOVIS. The intensity map and safety margins could be obtained for all available models. Conclusions GLIOVIS for 5-ALA-guided surgery image processing was validated on various gelatin-based brain models. Different levels of fluorescence could be qualitatively digitalized using this technique. These results need to be further confirmed and corroborated in vivo and validated clinically in order to define a new standard of care for glioblastoma resection.
Collapse
Affiliation(s)
- Marianne Mazevet
- Department of Innovative Technologies, University of Applied Sciences and Arts of Southern Switzerland, Lugano, Switzerland
| | - Christian Oberli
- Department of Innovative Technologies, University of Applied Sciences and Arts of Southern Switzerland, Lugano, Switzerland
| | - Sebastiano Marinelli
- Department of Innovative Technologies, University of Applied Sciences and Arts of Southern Switzerland, Lugano, Switzerland
| | - Ismail Zaed
- Department of Neurosurgery, Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland
| | - Stefanie Bauer
- Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland
| | - Alain Kaelin-Lang
- Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland
- Department of Neurology, Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland
- Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
| | - Francesco Marchi
- Department of Neurosurgery, Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland
| | - Roberto Gardenghi
- Department of Innovative Technologies, University of Applied Sciences and Arts of Southern Switzerland, Lugano, Switzerland
| | - Michael Reinert
- Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland
- Department of Neurosurgery, Hirslanden Neurological and Spinal Surgery Center, St. Anna Clinic, Lucerne, Switzerland
- Department of Neurosurgery, Inselspital University Hospital, University of Bern, Bern, Switzerland
| | - Andrea Cardia
- Department of Neurosurgery, Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland
| |
Collapse
|
2
|
Pravatà E, Diociasi A, Navarra R, Carmisciano L, Sormani MP, Roccatagliata L, Chincarini A, Ossola A, Cardia A, Cianfoni A, Kaelin-Lang A, Gobbi C, Zecca C. Biometry extraction and probabilistic anatomical atlas of the anterior Visual Pathway using dedicated high-resolution 3-D MRI. Sci Rep 2024; 14:453. [PMID: 38172589 PMCID: PMC10764933 DOI: 10.1038/s41598-023-50980-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2022] [Accepted: 12/28/2023] [Indexed: 01/05/2024] Open
Abstract
Anterior Visual Pathway (aVP) damage may be linked to diverse inflammatory, degenerative and/or vascular conditions. Currently however, a standardized methodological framework for extracting MRI biomarkers of the aVP is not available. We used high-resolution, 3-D MRI data to generate a probabilistic anatomical atlas of the normal aVP and its intraorbital (iOrb), intracanalicular (iCan), intracranial (iCran), optic chiasm (OC), and tract (OT) subdivisions. We acquired 0.6 mm3 steady-state free-precession images from 24 healthy participants using a 3 T scanner. aVP masks were obtained by manual segmentation of each aVP subdivision. Mask straightening and normalization with cross-sectional area (CSA) preservation were obtained using scripts developed in-house. A probabilistic atlas ("aVP-24") was generated by averaging left and right sides of all subjects. Leave-one-out cross-validation with respect to interindividual variability was performed employing the Dice Similarity Index (DSI). Spatially normalized representations of the aVP subdivisions were generated. Overlapping CSA values before and after normalization demonstrate preservation of the aVP cross-section. Volume, length, CSA, and ellipticity index (ε) biometrics were extracted. The aVP-24 morphology followed previous descriptions from the gross anatomy. Atlas spatial validation DSI scores of 0.85 in 50% and 0.77 in 95% of participants indicated good generalizability across the subjects. The proposed MRI standardization framework allows for previously unavailable, geometrically unbiased biometric data of the entire aVP and provides the base for future spatial-resolved, group-level investigations.
Collapse
Affiliation(s)
- Emanuele Pravatà
- Neurocenter of Southern Switzerland, EOC, Neuroradiology, Lugano, Switzerland.
- Faculty of Biomedical Sciences, Università Della Svizzera Italiana, Lugano, Switzerland.
| | - Andrea Diociasi
- Department of Health Sciences, University of Genova, Genova, Italy
| | - Riccardo Navarra
- Institute for Advanced Biomedical Technology (I.T.A.B.), Chieti, Italy
| | - Luca Carmisciano
- Department of Health Sciences, University of Genova, Genova, Italy
| | | | | | | | - Alessandra Ossola
- Neurocenter of Southern Switzerland, EOC, Ophthalmology, Lugano, Switzerland
- Neurocenter of Southern Switzerland, EOC, Neurosurgery, Lugano, Switzerland
| | - Andrea Cardia
- Neurocenter of Southern Switzerland, EOC, Neurosurgery, Lugano, Switzerland
| | - Alessandro Cianfoni
- Neurocenter of Southern Switzerland, EOC, Neuroradiology, Lugano, Switzerland
- Faculty of Biomedical Sciences, Università Della Svizzera Italiana, Lugano, Switzerland
| | - Alain Kaelin-Lang
- Faculty of Biomedical Sciences, Università Della Svizzera Italiana, Lugano, Switzerland
- Neurocenter of Southern Switzerland, EOC, Neurology, Lugano, Switzerland
| | - Claudio Gobbi
- Faculty of Biomedical Sciences, Università Della Svizzera Italiana, Lugano, Switzerland
- Neurocenter of Southern Switzerland, EOC, Neurology, Lugano, Switzerland
| | - Chiara Zecca
- Faculty of Biomedical Sciences, Università Della Svizzera Italiana, Lugano, Switzerland
- Neurocenter of Southern Switzerland, EOC, Neurology, Lugano, Switzerland
| |
Collapse
|
3
|
Pinton S, Vacchi E, Chiaro G, Raimondi A, Tzankov A, Gerber B, Gobbi C, Kaelin-Lang A, Melli G. Amyloid detection and typing yield of skin biopsy in systemic amyloidosis and polyneuropathy. Ann Clin Transl Neurol 2023; 10:2347-2359. [PMID: 37849451 PMCID: PMC10723241 DOI: 10.1002/acn3.51924] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2023] [Revised: 09/26/2023] [Accepted: 09/28/2023] [Indexed: 10/19/2023] Open
Abstract
OBJECTIVE Disease-modifying therapies are available for amyloidosis but are ineffective if end-organ damage is severe. As small fiber neuropathy is an early and common feature of amyloidosis, we assessed detection and typing yield of skin biopsy for amyloid in patients with confirmed systemic amyloidosis and neuropathic symptoms. METHODS In this case-control study, patients with transthyretin and light chain amyloidosis (ATTRv, ATTRwt, and AL) were consecutively recruited. They were sex and age-matched to three control groups (1) non-neuropathic controls (NNC), (2) monoclonal gammopathy of undetermined significance (MGUS), and (3) other neuropathic disease controls (ONC). Patients underwent a double 3 mm skin biopsy in proximal and distal leg. Amyloid index and burden, protein typing by immuno-electron microscopy, intraepidermal nerve fiber density, electroneuromyography, and clinical characteristics were analyzed. RESULTS We studied 15 subjects with confirmed systemic amyloidosis, 20 NNC, 18 MGUS, and 20 ONC. Amyloid was detected in 100% of patients with amyloidosis (87% in ankle and 73% in thigh). It was not detected in any of the control groups. A small fiber neuropathy was encountered in 100% of amyloidosis patients, in 80% of MGUS, and in 78% of ONC. Amyloid burden was higher in ATTRv, followed by AL and ATTRwt. The ultrastructural examination allowed the identification of the precursor protein by immunotyping in most of the cases. INTERPRETATION Skin biopsy is a minimally invasive test with optimal sensitivity for amyloid. It allows amyloid typing by electron microscope to identify the precursor protein. The diagnostic work up of systemic amyloidosis should include a skin biopsy.
Collapse
Affiliation(s)
- Sandra Pinton
- Neurology Department, Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland
- Neurodegenerative disorders lab, Laboratories for Translational Research, Ente Ospedaliero Cantonale, Bellinzona, Switzerland
| | - Elena Vacchi
- Neurology Department, Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland
- Neurodegenerative disorders lab, Laboratories for Translational Research, Ente Ospedaliero Cantonale, Bellinzona, Switzerland
- Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland
| | - Giacomo Chiaro
- Neurology Department, Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland
- Neurodegenerative disorders lab, Laboratories for Translational Research, Ente Ospedaliero Cantonale, Bellinzona, Switzerland
| | - Andrea Raimondi
- Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland
- Experimental Imaging Centre, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Alexandar Tzankov
- Histopathology, Institute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland
| | - Bernhard Gerber
- Clinic of Hematology, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland
- University of Zurich, Zurich, Switzerland
| | - Claudio Gobbi
- Neurology Department, Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland
- Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland
| | - Alain Kaelin-Lang
- Neurology Department, Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland
- Neurodegenerative disorders lab, Laboratories for Translational Research, Ente Ospedaliero Cantonale, Bellinzona, Switzerland
- Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland
- Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
| | - Giorgia Melli
- Neurology Department, Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland
- Neurodegenerative disorders lab, Laboratories for Translational Research, Ente Ospedaliero Cantonale, Bellinzona, Switzerland
- Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland
| |
Collapse
|
4
|
Amato N, Caverzasio S, Manconi M, Staedler C, Kaelin-Lang A, Galati S. Slow wave activity across sleep-night could predict levodopa-induced dyskinesia. Sci Rep 2023; 13:15468. [PMID: 37726375 PMCID: PMC10509191 DOI: 10.1038/s41598-023-42604-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2023] [Accepted: 09/12/2023] [Indexed: 09/21/2023] Open
Abstract
A disruption in the slow wave activity (SWA) mediated synaptic downscaling process features Parkinson's disease (PD) patients presenting levodopa-induced dyskinesia (LID). To corroborate the role of SWA in LID development, 15 PD patients with LID, who underwent a polysomnography before LID's appearance, were included. Slow wave sleep epochs were extracted, combined and segmented into early and late sleep. SWA power was calculated. A linear regression model established that the SWA overnight decrease could predict the time to the emergence of LID. Our finding supports the link between SWA-mediated synaptic downscaling and the development of LID. If confirmed, it could pave the way to the study of possible sleep targeted therapies able to protect PD patients from LID development.
Collapse
Affiliation(s)
- Ninfa Amato
- Parkinson Disease and Movement Disorder Center, Neurocenter of Southern Switzerland, EOC, Via Tesserete 46, 6903, Lugano, Switzerland
| | - Serena Caverzasio
- Parkinson Disease and Movement Disorder Center, Neurocenter of Southern Switzerland, EOC, Via Tesserete 46, 6903, Lugano, Switzerland
- Faculty of Biomedical Sciences, Università Della Svizzera Italiana (USI), Via Giuseppe Buffi 13, Lugano, Switzerland
| | - Mauro Manconi
- Parkinson Disease and Movement Disorder Center, Neurocenter of Southern Switzerland, EOC, Via Tesserete 46, 6903, Lugano, Switzerland
- Faculty of Biomedical Sciences, Università Della Svizzera Italiana (USI), Via Giuseppe Buffi 13, Lugano, Switzerland
- Department of Neurology, Inselspital, Bern University Hospital, Freiburgstrasse 18, Bern, Switzerland
| | - Claudio Staedler
- Parkinson Disease and Movement Disorder Center, Neurocenter of Southern Switzerland, EOC, Via Tesserete 46, 6903, Lugano, Switzerland
| | - Alain Kaelin-Lang
- Parkinson Disease and Movement Disorder Center, Neurocenter of Southern Switzerland, EOC, Via Tesserete 46, 6903, Lugano, Switzerland
- Faculty of Biomedical Sciences, Università Della Svizzera Italiana (USI), Via Giuseppe Buffi 13, Lugano, Switzerland
- Department of Neurology, Inselspital, Bern University Hospital, Freiburgstrasse 18, Bern, Switzerland
| | - Salvatore Galati
- Parkinson Disease and Movement Disorder Center, Neurocenter of Southern Switzerland, EOC, Via Tesserete 46, 6903, Lugano, Switzerland.
- Faculty of Biomedical Sciences, Università Della Svizzera Italiana (USI), Via Giuseppe Buffi 13, Lugano, Switzerland.
| |
Collapse
|
5
|
Danieli L, Roccatagliata L, Distefano D, Prodi E, Riccitelli GC, Diociasi A, Carmisciano L, Cianfoni A, Bartalena T, Kaelin-Lang A, Gobbi C, Zecca C, Pravatà E. Nonlesional Sources of Contrast Enhancement on Postgadolinium "Black-Blood" 3D T1-SPACE Images in Patients with Multiple Sclerosis. AJNR Am J Neuroradiol 2022; 43:872-880. [PMID: 35618421 DOI: 10.3174/ajnr.a7529] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2021] [Accepted: 04/08/2022] [Indexed: 11/07/2022]
Abstract
BACKGROUND AND PURPOSE We hypothesized that 3D T1-TSE "black-blood" images may carry an increased risk of contrast-enhancing lesion misdiagnosis in patients with MS because of the misinterpretation of intraparenchymal vein enhancement. Thus, the occurrence of true-positive and false-positive findings was compared between standard MPRAGE and volumetric interpolated brain examination techniques. MATERIALS AND METHODS Sampling perfection with application-optimized contrasts by using different flip-angle evolution (SPACE) images obtained from 232 patients with MS, clinically isolated syndrome, or radiologically isolated syndrome were compared with standard MPRAGE and volumetric interpolated brain examination images. The intraparenchymal vein contrast-to-noise ratio was estimated at the level of the thalami. Contrast-enhancing lesions were blindly detected by 2 expert readers and 1 beginner reader. True- and false-positives were determined by senior readers' consensus. True-positive and false-positive frequency differences and patient-level diagnosis probability were tested with the McNemar test and OR. The contrast-to-noise ratio and morphology were compared using the Mann-Whitney U and χ2 tests. RESULTS The intraparenchymal vein contrast-to-noise ratio was higher in SPACE than in MPRAGE and volumetric interpolated brain examination images (P < .001, both). There were 66 true-positives and 74 false-positives overall. SPACE detected more true-positive and false-positive results (P range < .001-.07) but did not increase the patient's true-positive likelihood (OR = 1 1.29, P = .478-1). However, the false-positive likelihood was increased (OR = 3.03-3.55, P = .008-.027). Venous-origin false-positives (n = 59) with contrast-to-noise ratio and morphology features similar to small-sized (≤14 mm3 P = .544) true-positives occurred more frequently in SPACE images (P < .001). CONCLUSIONS Small intraparenchymal veins may confound the diagnosis of enhancing lesions on postgadolinium black-blood SPACE images.
Collapse
Affiliation(s)
- L Danieli
- Form the Department of Neuroradiology (L.D., E. Prodi, A.C., E. Pravatà), Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland
| | - L Roccatagliata
- Dipartimento di Scienze della Salute (L.R., A.D.), Università degli Studi di Genova, Genoa, Italy
| | | | - E Prodi
- Form the Department of Neuroradiology (L.D., E. Prodi, A.C., E. Pravatà), Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland
| | - G C Riccitelli
- Department of Neurology (G.C.R., A.K.-L., C.G., C.Z., E. Pravatà), Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland.,Faculty of Biomedical Sciences (G.C.R., A.C., A.K.-L., C.G., C,Z., E. Pravatà), Università della Svizzera Italiana, Lugano, Switzerland
| | - A Diociasi
- Dipartimento di Scienze della Salute (L.R., A.D.), Università degli Studi di Genova, Genoa, Italy
| | - L Carmisciano
- Department of Health Sciences, Section of Biostatistics (L.C.), Università degli Studi di Genova, Genoa, Italy
| | - A Cianfoni
- Form the Department of Neuroradiology (L.D., E. Prodi, A.C., E. Pravatà), Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland.,Faculty of Biomedical Sciences (G.C.R., A.C., A.K.-L., C.G., C,Z., E. Pravatà), Università della Svizzera Italiana, Lugano, Switzerland
| | - T Bartalena
- Department of Radiology (T.B.), Pol. Zappi Bartalena, Imola, Italy
| | - A Kaelin-Lang
- Department of Neurology (G.C.R., A.K.-L., C.G., C.Z., E. Pravatà), Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland.,Faculty of Biomedical Sciences (G.C.R., A.C., A.K.-L., C.G., C,Z., E. Pravatà), Università della Svizzera Italiana, Lugano, Switzerland
| | - C Gobbi
- Department of Neurology (G.C.R., A.K.-L., C.G., C.Z., E. Pravatà), Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland.,Faculty of Biomedical Sciences (G.C.R., A.C., A.K.-L., C.G., C,Z., E. Pravatà), Università della Svizzera Italiana, Lugano, Switzerland
| | - C Zecca
- Department of Neurology (G.C.R., A.K.-L., C.G., C.Z., E. Pravatà), Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland.,Faculty of Biomedical Sciences (G.C.R., A.C., A.K.-L., C.G., C,Z., E. Pravatà), Università della Svizzera Italiana, Lugano, Switzerland
| | - E Pravatà
- Form the Department of Neuroradiology (L.D., E. Prodi, A.C., E. Pravatà), Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland .,Faculty of Biomedical Sciences (G.C.R., A.C., A.K.-L., C.G., C,Z., E. Pravatà), Università della Svizzera Italiana, Lugano, Switzerland
| |
Collapse
|
6
|
Vacchi E, Lazzarini E, Pinton S, Chiaro G, Disanto G, Marchi F, Robert T, Staedler C, Galati S, Gobbi C, Barile L, Kaelin-Lang A, Melli G. Tau protein quantification in skin biopsies differentiates tauopathies from alpha-synucleinopathies. Brain 2022; 145:2755-2768. [PMID: 35485527 DOI: 10.1093/brain/awac161] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2022] [Revised: 04/03/2022] [Accepted: 04/19/2022] [Indexed: 11/12/2022] Open
Abstract
Abnormal accumulation of microtubule-associated protein tau (τ) is a characteristic feature of atypical parkinsonisms with tauopathies such as Progressive Supranuclear Palsy (PSP) and Corticobasal Degeneration (CBD). However, pathological τ has also been observed in α-synucleinopathies like Parkinson's Disease (PD) and Multiple System Atrophy (MSA). Based on the involvement of peripheral nervous system in several neurodegenerative diseases, we characterized and compared τ expression in skin biopsies of patients clinically diagnosed with PD, MSA, PSP, CBD, and in healthy control subjects. In all groups, τ protein was detected along both somatosensory and autonomic nerve fibers in the epidermis and dermis by immunofluorescence. We found by western blot the presence of mainly two different bands at 55 and 70 KDa, co-migrating with 0N4R/1N3R and 2N4R isoforms, respectively. At the RNA level, the main transcript variants were 2N and 4R, and both resulted more expressed in PSP/CBD by real-time PCR. ELISA assay demonstrated significantly higher levels of total τ protein in skin lysates of PSP/CBD compared to the other groups. Multivariate regression analysis and ROC curves analysis of τ amount at both sites showed a clinical association with tauopathies diagnosis and high diagnostic value for PSP/CBD vs. PD (sensitivity 90%, specificity 69%) and PSP/CBD vs. MSA (sensitivity 90%, specificity 86%). τ protein increase correlated with cognitive impairment in PSP/CBD. This study is a comprehensive characterization of τ in the human cutaneous peripheral nervous system in physiologic and pathologic conditions. The differential expression of τ, both at transcript and protein levels, suggests that skin biopsy, an easily accessible and minimally invasive exam, can help in discriminating among different neurodegenerative diseases.
Collapse
Affiliation(s)
- Elena Vacchi
- Laboratory for Biomedical Neurosciences, Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland.,Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland
| | - Edoardo Lazzarini
- Laboratory for Cardiovascular Theranostics, Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale, Lugano, Switzerland
| | - Sandra Pinton
- Laboratory for Biomedical Neurosciences, Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland
| | - Giacomo Chiaro
- Laboratory for Biomedical Neurosciences, Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland.,Neurology Department, Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland
| | - Giulio Disanto
- Neurology Department, Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland
| | - Francesco Marchi
- Neurosurgery Department, Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland
| | - Thomas Robert
- Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland.,Neurosurgery Department, Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland
| | - Claudio Staedler
- Neurology Department, Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland
| | - Salvatore Galati
- Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland.,Neurology Department, Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland
| | - Claudio Gobbi
- Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland.,Neurology Department, Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland
| | - Lucio Barile
- Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland.,Laboratory for Cardiovascular Theranostics, Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale, Lugano, Switzerland.,Institute of Life Science, Scuola Superiore Sant'Anna, Pisa, Italy
| | - Alain Kaelin-Lang
- Laboratory for Biomedical Neurosciences, Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland.,Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland.,Neurology Department, Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland.,Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
| | - Giorgia Melli
- Laboratory for Biomedical Neurosciences, Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland.,Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland.,Neurology Department, Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland
| |
Collapse
|
7
|
Hartmann M, Falconer CJ, Kaelin-Lang A, Müri RM, Mast FW. Imagined paralysis reduces motor cortex excitability. Psychophysiology 2022; 59:e14069. [PMID: 35393640 PMCID: PMC9539708 DOI: 10.1111/psyp.14069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2020] [Revised: 12/16/2021] [Accepted: 03/26/2022] [Indexed: 11/27/2022]
Abstract
Mental imagery is a powerful capability that engages similar neurophysiological processes that underlie real sensory and motor experiences. Previous studies show that motor cortical excitability can increase during mental imagery of actions. In this study, we focused on possible inhibitory effects of mental imagery on motor functions. We assessed whether imagined arm paralysis modulates motor cortical excitability in healthy participants, as measured by motor evoked potentials (MEPs) of the hand induced by near-threshold transcranial magnetic stimulation (TMS) over the primary motor cortex hand area. We found lower MEP amplitudes during imagined arm paralysis when compared to imagined leg paralysis or baseline stimulation without paralysis imagery. These results show that purely imagined bodily constraints can selectively inhibit basic motor corticospinal functions. The results are discussed in the context of motoric embodiment/disembodiment.
Collapse
Affiliation(s)
- Matthias Hartmann
- Department of Psychology, University of Bern, Bern, Switzerland.,Faculty of Psychology, UniDistance Suisse, Brig, Switzerland
| | - Caroline J Falconer
- Department of Psychology, University of Bern, Bern, Switzerland.,Department of Clinical Educational and Health Psychology, University College London, London, UK
| | - Alain Kaelin-Lang
- Department of Neurology, University Hospital, University of Bern, Bern, Switzerland.,Department of BioMedical Research, University Hospital, University of Bern, Bern, Switzerland.,Neurocenter of Southern Switzerland, Regional Hospital of Lugano, Lugano, Switzerland.,Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland
| | - René M Müri
- Department of Neurology, University Hospital, University of Bern, Bern, Switzerland.,Department of BioMedical Research, University Hospital, University of Bern, Bern, Switzerland
| | - Fred W Mast
- Department of Psychology, University of Bern, Bern, Switzerland
| |
Collapse
|
8
|
Stieglitz LH, Oertel MF, Accolla EA, Bally J, Bauer R, Baumann CR, Benninger D, Bohlhalter S, Büchele F, Hägele-Link S, Kägi G, Krack P, Krüger MT, Mahendran S, Möller JC, Mylius V, Piroth T, Werner B, Kaelin-Lang A. Consensus Statement on High-Intensity Focused Ultrasound for Functional Neurosurgery in Switzerland. Front Neurol 2021; 12:722762. [PMID: 34630296 PMCID: PMC8493868 DOI: 10.3389/fneur.2021.722762] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2021] [Accepted: 08/18/2021] [Indexed: 11/17/2022] Open
Abstract
Background: Magnetic resonance-guided high-intensity focused ultrasound (MRgHiFUS) has evolved into a viable ablative treatment option for functional neurosurgery. However, it is not clear yet, how this new technology should be integrated into current and established clinical practice and a consensus should be found about recommended indications, stereotactic targets, patient selection, and outcome measurements. Objective: To sum up and unify current knowledge and clinical experience of Swiss neurological and neurosurgical communities regarding MRgHiFUS interventions for brain disorders to be published as a national consensus paper. Methods: Eighteen experienced neurosurgeons and neurologists practicing in Switzerland in the field of movement disorders and one health physicist representing 15 departments of 12 Swiss clinical centers and 5 medical societies participated in the workshop and contributed to the consensus paper. All experts have experience with current treatment modalities or with MRgHiFUS. They were invited to participate in two workshops and consensus meetings and one online meeting. As part of workshop preparations, a thorough literature review was undertaken and distributed among participants together with a list of relevant discussion topics. Special emphasis was put on current experience and practice, and areas of controversy regarding clinical application of MRgHiFUS for functional neurosurgery. Results: The recommendations addressed lesioning for treatment of brain disorders in general, and with respect to MRgHiFUS indications, stereotactic targets, treatment alternatives, patient selection and management, standardization of reporting and follow-up, and initialization of a national registry for interventional therapies of movement disorders. Good clinical evidence is presently only available for unilateral thalamic lesioning in treating essential tremor or tremor-dominant Parkinson's disease and, to a minor extent, for unilateral subthalamotomy for Parkinson's disease motor features. However, the workgroup unequivocally recommends further exploration and adaptation of MRgHiFUS-based functional lesioning interventions and confirms the need for outcome-based evaluation of these approaches based on a unified registry. MRgHiFUS and DBS should be evaluated by experts familiar with both methods, as they are mutually complementing therapy options to be appreciated for their distinct advantages and potential. Conclusion: This multidisciplinary consensus paper is a representative current recommendation for safe implementation and standardized practice of MRgHiFUS treatments for functional neurosurgery in Switzerland.
Collapse
Affiliation(s)
| | - Markus F Oertel
- Department of Neurosurgery, University Hospital Zurich, Zurich, Switzerland
| | - Ettore A Accolla
- Neurology Unit, Department of Internal Medicine, Hôpital Fribourgeois (HFR)-Cantonal Hospital Fribourg, University of Fribourg, Fribourg, Switzerland
| | - Julien Bally
- Department of Neurology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.,Department of Neurology, Geneva University Hospital and University of Geneva, Geneva, Switzerland
| | - Roland Bauer
- Department of Neurosurgery, Cantonal Hospital Aarau, Aarau, Switzerland
| | | | - David Benninger
- Department of Neurology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
| | - Stephan Bohlhalter
- Neurocenter, Lucerne Cantonal Hospital, University of Zurich, Zurich, Switzerland
| | - Fabian Büchele
- Department of Neurology, University Hospital Zurich, Zurich, Switzerland
| | - Stefan Hägele-Link
- Department of Neurology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland
| | - Georg Kägi
- Department of Neurology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland
| | - Paul Krack
- Department of Neurology, Inselspital, University Bern, Bern, Switzerland
| | - Marie T Krüger
- Department of Neurosurgery, Cantonal Hospital St. Gallen, St. Gallen, Switzerland
| | - Sujitha Mahendran
- Department of Neurology, University Hospital Zurich, Zurich, Switzerland
| | - J Carsten Möller
- Parkinson Center, Center for Neurological Rehabilitation, Zihlschlacht, Switzerland
| | - Veit Mylius
- Department of Neurology, Center for Neurorehabilitation, Valens, Switzerland
| | - Tobias Piroth
- Department of Neurology, Cantonal Hospital Aarau, Aarau, Switzerland
| | - Beat Werner
- Center for Magnetic Resonance (MR) Research, University Children's Hospital Zurich, Zurich, Switzerland
| | - Alain Kaelin-Lang
- Department of Neurology, Inselspital, University Bern, Bern, Switzerland.,Neurocenter of Southern Switzerland Ente Ospedaliero Cantonale (EOC), Regional Hospital Lugano, Lugano, Switzerland.,Faculty of Biomedical Neurosciences, Università Della Svizzera Italiana, Lugano, Switzerland
| |
Collapse
|
9
|
Mascheroni A, Choe EK, Luo Y, Marazza M, Ferlito C, Caverzasio S, Mezzanotte F, Kaelin-Lang A, Faraci F, Puiatti A, Ratti PL. The SleepFit Tablet Application for Home-Based Clinical Data Collection in Parkinson Disease: User-Centric Development and Usability Study. JMIR Mhealth Uhealth 2021; 9:e16304. [PMID: 34100767 PMCID: PMC8262669 DOI: 10.2196/16304] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2019] [Revised: 10/31/2020] [Accepted: 03/26/2021] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Parkinson disease (PD) is a common, multifaceted neurodegenerative disorder profoundly impacting patients' autonomy and quality of life. Assessment in real-life conditions of subjective symptoms and objective metrics of mobility and nonmotor symptoms such as sleep disturbance is strongly advocated. This information would critically guide the adaptation of antiparkinsonian medications and nonpharmacological interventions. Moreover, since the spread of the COVID-19 pandemic, health care practices are being reshaped toward a more home-based care. New technologies could play a pivotal role in this new approach to clinical care. Nevertheless, devices and information technology tools might be unhandy for PD patients, thus dramatically limiting their widespread employment. OBJECTIVE The goals of the research were development and usability evaluation of an application, SleepFit, for ecological momentary assessment of objective and subjective clinical metrics at PD patients' homes, and as a remote tool for researchers to monitor patients and integrate and manage data. METHODS An iterative and user-centric strategy was employed for the development of SleepFit. The core structure of SleepFit consists of (1) an electronic finger-tapping test; (2) motor, sleepiness, and emotional subjective scales; and (3) a sleep diary. Applicable design, ergonomic, and navigation principles have been applied while tailoring the application to the specific patient population. Three progressively enhanced versions of the application (alpha, v1.0, v2.0) were tested by a total of 56 patients with PD who were asked to perform multiple home assessments 4 times per day for 2 weeks. Patient compliance was calculated as the proportion of completed tasks out of the total number of expected tasks. Satisfaction on the latest version (v2.0) was evaluated as potential willingness to use SleepFit again after the end of the study. RESULTS From alpha to v1.0, SleepFit was improved in graphics, ergonomics, and navigation, with automated flows guiding the patients in performing tasks throughout the 24 hours, and real-time data collection and consultation were made possible thanks to a remote web portal. In v2.0, the kiosk-mode feature restricts the use of the tablet to the SleepFit application only, thus preventing users from accidentally exiting the application. A total of 52 (4 dropouts) patients were included in the analyses. Overall compliance (all versions) was 88.89% (5707/6420). SleepFit was progressively enhanced and compliance increased from 87.86% (2070/2356) to 89.92% (2899/3224; P=.04). Among the patients who used v2.0, 96% (25/26) declared they would use SleepFit again. CONCLUSIONS SleepFit can be considered a state-of-the-art home-based system that increases compliance in PD patients, ensures high-quality data collection, and works as a handy tool for remote monitoring and data management in clinical research. Thanks to its user-friendliness and modular structure, it could be employed in other clinical studies with minimum adaptation efforts. TRIAL REGISTRATION ClinicalTrials.gov NCT02723396; https://clinicaltrials.gov/ct2/show/NCT02723396.
Collapse
Affiliation(s)
- Alessandro Mascheroni
- Institute of Information Systems and Networking, Department of Innovative Technologies, University of Applied Sciences and Arts of Southern Switzerland, Lugano, Switzerland
| | - Eun Kyoung Choe
- College of Information Studies, University of Maryland, College Park, MD, United States
| | - Yuhan Luo
- College of Information Studies, University of Maryland, College Park, MD, United States
| | - Michele Marazza
- Information & Communication Technology, Ente Ospedaliero Cantonale, Bellinzona, Switzerland
| | - Clara Ferlito
- Neurocenter of Southern Switzerland, Lugano, Switzerland
| | | | | | - Alain Kaelin-Lang
- Neurocenter of Southern Switzerland, Lugano, Switzerland.,Faculty of Biomedical Sciences, University of Southern Switzerland, Lugano, Switzerland.,Medical School, University of Bern, Bern, Switzerland
| | - Francesca Faraci
- Institute of Information Systems and Networking, Department of Innovative Technologies, University of Applied Sciences and Arts of Southern Switzerland, Lugano, Switzerland
| | - Alessandro Puiatti
- Institute of Information Systems and Networking, Department of Innovative Technologies, University of Applied Sciences and Arts of Southern Switzerland, Lugano, Switzerland
| | | |
Collapse
|
10
|
Pravatà E, Roccatagliata L, Sormani MP, Carmisciano L, Lienerth C, Sacco R, Kaelin-Lang A, Cianfoni A, Zecca C, Gobbi C. Dedicated 3D-T2-STIR-ZOOMit Imaging Improves Demyelinating Lesion Detection in the Anterior Visual Pathways of Patients with Multiple Sclerosis. AJNR Am J Neuroradiol 2021; 42:1061-1068. [PMID: 33766824 DOI: 10.3174/ajnr.a7082] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2020] [Accepted: 12/20/2020] [Indexed: 11/07/2022]
Abstract
BACKGROUND AND PURPOSE Demyelinating lesions in the anterior visual pathways represent an underestimated marker of disease dissemination in patients with MS. We prospectively investigated whether a dedicated high-resolution MR imaging technique, the 3D-T2-STIR-ZOOMit, improves demyelinating lesion detection compared with the current clinical standard sequence, the 2D-T2-STIR. MATERIALS AND METHODS 3T MR imaging of the anterior visual pathways (optic nerves, chiasm, and tracts) was performed using 3D-T2-STIR-ZOOMit and 2D-T2-STIR, in patients with MS and healthy controls. Two experienced neuroradiologists assessed, independently, demyelinating lesions using both sequences separately. 3D-T2-STIR-ZOOMit scan-rescan reproducibility was tested in 12 patients. The Cohen κ was used for interrater agreement, and the intraclass correlation coefficient for reproducibility. Between-sequence detection differences and the effects of location and previous acute optic neuritis were assessed using a binomial mixed-effects model. RESULTS Forty-eight patients with MS with (n = 19) or without (n = 29) past optic neuritis and 19 healthy controls were evaluated. Readers' agreement was strong (3D-T2-STIR-ZOOMit: 0.85; 2D-T2-STIR: 0.90). The 3D-T2-STIR-ZOOMit scan-rescan intraclass correlation coefficient was 0.97 (95% CI, 0.96-0.98; P < .001), indicating excellent reproducibility. Overall, 3D-T2-STIR-ZOOMit detected more than twice the demyelinating lesions (n = 89) than 2D-T2-STIR (n = 43) (OR = 2.7; 95% CI, 1.7-4.1; P < .001). In the intracranial anterior visual pathway segments, 33 of the 36 demyelinating lesions (91.7%) detected by 3D-T2-STIR-ZOOMit were not disclosed by 2D-T2-STIR. 3D-T2-STIR-ZOOMit increased detection of demyelinating lesion probability by 1.8-fold in patients with past optic neuritis (OR = 1.8; 95% CI, 1.2-3.1; P = .01) and 5.9-fold in patients without past optic neuritis (OR = 5.9; 95% CI, 2.5-13.8; P < .001). No false-positive demyelinating lesions were detected in healthy controls. CONCLUSIONS Dedicated 3D-T2-STIR-ZOOMit images improved substantially the detection of MS disease dissemination in the anterior visual pathways, particularly in the intracranial segments and in patients without past optic neuritis.
Collapse
Affiliation(s)
- E Pravatà
- From the Department of Neuroradiology (E.P., A.C.), Neurocenter of Southern Switzerland, Lugano, Switzerland
| | - L Roccatagliata
- Department of Health Sciences (L.R., M.P.S., L.C.), University of Genova, Genova, Italy.,Dipartimento di Scienze della Salute - DISSAL (L.R., M.P.S.), Istituto di Ricovero e Cura a Carattere Scientifico Ospedale Policlinico San Martino, Genoa, Italy
| | - M P Sormani
- Department of Health Sciences (L.R., M.P.S., L.C.), University of Genova, Genova, Italy.,Dipartimento di Scienze della Salute - DISSAL (L.R., M.P.S.), Istituto di Ricovero e Cura a Carattere Scientifico Ospedale Policlinico San Martino, Genoa, Italy
| | - L Carmisciano
- Department of Health Sciences (L.R., M.P.S., L.C.), University of Genova, Genova, Italy
| | - C Lienerth
- Bayer Vital GmbH (C.L.), Leverkusen, Germany
| | - R Sacco
- Department of Neurology (R.S., A.K.-L., C.Z., C.G.), Neurocenter of Southern Switzerland, Lugano, Switzerland
| | - A Kaelin-Lang
- Department of Neurology (R.S., A.K.-L., C.Z., C.G.), Neurocenter of Southern Switzerland, Lugano, Switzerland.,Faculty of Biomedical Sciences (A.K.-L., A.C., C.Z., C.G.), Università della Svizzera Italiana, Lugano, Switzerland
| | - A Cianfoni
- From the Department of Neuroradiology (E.P., A.C.), Neurocenter of Southern Switzerland, Lugano, Switzerland.,Faculty of Biomedical Sciences (A.K.-L., A.C., C.Z., C.G.), Università della Svizzera Italiana, Lugano, Switzerland
| | - C Zecca
- Department of Neurology (R.S., A.K.-L., C.Z., C.G.), Neurocenter of Southern Switzerland, Lugano, Switzerland.,Faculty of Biomedical Sciences (A.K.-L., A.C., C.Z., C.G.), Università della Svizzera Italiana, Lugano, Switzerland
| | - C Gobbi
- Department of Neurology (R.S., A.K.-L., C.Z., C.G.), Neurocenter of Southern Switzerland, Lugano, Switzerland.,Faculty of Biomedical Sciences (A.K.-L., A.C., C.Z., C.G.), Università della Svizzera Italiana, Lugano, Switzerland
| |
Collapse
|
11
|
Steiner L, Homan S, Everts R, Federspiel A, Kamal S, Rodriguez JAD, Kornfeld S, Slavova N, Wiest R, Kaelin-Lang A, Steinlin M, Grunt S. Functional connectivity and upper limb function in patients after pediatric arterial ischemic stroke with contralateral corticospinal tract wiring. Sci Rep 2021; 11:5490. [PMID: 33750854 PMCID: PMC7943570 DOI: 10.1038/s41598-021-84671-2] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2020] [Accepted: 02/17/2021] [Indexed: 12/29/2022] Open
Abstract
To develop individualized motor rehabilitation, knowledge of the relationship between neuroplastic reorganization and motor recovery after pediatric arterial ischemic stroke (AIS) is crucial. Thus, we investigated functional connectivity in patients after AIS with good motor outcome and in patients with hemiparesis compared with typically developing peers. We included 18 patients (n = 9 with hemiparesis, n = 9 with good motor outcome) with pediatric AIS in the chronic phase (≥ 2 years after diagnosis, diagnosed > 16 years) and 18 peers matched by age and gender. Participants underwent a standardized motor assessment, single-pulse transcranial magnetic stimulation to determine the type of corticospinal tract wiring, and resting-state functional magnetic resonance imaging to examine motor network connectivity. Corticospinal tract wiring was contralateral in all participants. Patients with hemiparesis had lower interhemispheric connectivity strength compared with patients with good clinical outcome and peers. Patients with good clinical outcome had higher intrahemispheric connectivity strength compared with peers. Further, higher intrahemispheric connectivity was related to better motor outcome in patients. Our findings suggest that better motor outcome after pediatric AIS is related to higher motor network connectivity strength. Thus, resting-state functional connectivity might be predictive for motor recovery after pediatric AIS.
Collapse
Affiliation(s)
- Leonie Steiner
- Division of Neuropediatrics, Development and Rehabilitation, University Children's Hospital, Inselspital, Freiburgstrasse 31, 3010, Bern, Switzerland.
- Graduate School for Health Sciences, University of Bern, Bern, Switzerland.
| | - Stephanie Homan
- Division of Systems Neuroscience, Translational Research Center, University Hospital of Psychiatry and Psychotherapy, Bern, Switzerland
- Department of Psychiatry, Psychotherapy and Psychosomatics, University Hospital of Psychiatry, University of Zurich, Zurich, Switzerland
| | - Regula Everts
- Division of Neuropediatrics, Development and Rehabilitation, University Children's Hospital, Inselspital, Freiburgstrasse 31, 3010, Bern, Switzerland
| | - Andrea Federspiel
- Division of Systems Neuroscience, Translational Research Center, University Hospital of Psychiatry and Psychotherapy, Bern, Switzerland
- Psychiatric Neuroimaging Unit, Translational Research Center, University Hospital of Psychiatry and Psychotherapy, Bern, Switzerland
| | - Sandeep Kamal
- Division of Neuropediatrics, Development and Rehabilitation, University Children's Hospital, Inselspital, Freiburgstrasse 31, 3010, Bern, Switzerland
| | - Juan Antonio Delgado Rodriguez
- Division of Neuropediatrics, Development and Rehabilitation, University Children's Hospital, Inselspital, Freiburgstrasse 31, 3010, Bern, Switzerland
- Graduate School for Health Sciences, University of Bern, Bern, Switzerland
| | - Salome Kornfeld
- Division of Neuropediatrics, Development and Rehabilitation, University Children's Hospital, Inselspital, Freiburgstrasse 31, 3010, Bern, Switzerland
| | - Nedelina Slavova
- Department of Diagnostic and Interventional Neuroradiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
| | - Roland Wiest
- Department of Diagnostic and Interventional Neuroradiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
| | - Alain Kaelin-Lang
- Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland
- Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
- Faculty of Biomedical Neurosciences, Università Della Svizzera Italiana, Lugano, Switzerland
| | - Maja Steinlin
- Division of Neuropediatrics, Development and Rehabilitation, University Children's Hospital, Inselspital, Freiburgstrasse 31, 3010, Bern, Switzerland
| | - Sebastian Grunt
- Division of Neuropediatrics, Development and Rehabilitation, University Children's Hospital, Inselspital, Freiburgstrasse 31, 3010, Bern, Switzerland
| |
Collapse
|
12
|
Möller JC, Baumann CR, Burkhard PR, Kaelin-Lang A, Küng I, Onuk K, Bohlhalter S. Characterisation of advanced Parkinson's disease: OBSERVE-PD observational study - results of the Swiss subgroup. Swiss Med Wkly 2021; 151:w20419. [PMID: 33705561 DOI: 10.4414/smw.2021.20419] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
AIMS OF THE STUDY Currently, the characterisation of advanced Parkinson’s disease (APD) does not follow standardised diagnostic criteria, which complicates the evaluation of ongoing care and treatment strategies, such as eligibility for device-aided treatment (DAT). Therefore, this study aimed to determine the proportion of APD and non-advanced Parkinson’s disease (non-APD) patients treated at specialised movement disorder centres in Switzerland, to compare clinical characteristics of APD versus non-APD patients and to assess eligibility for and use of DAT. Furthermore, potential differences between the Swiss and international situation should be uncovered. METHODS OBSERVE-PD was a cross-sectional, international, observational study including 2615 patients from 128 movement disorder centres in 18 countries. For the Swiss subgroup of the study analysed here, which included 134 patients from 5 movement disorder centres, motor and non-motor symptoms, activities of daily living and quality of life were assessed as endpoints. The correlation between physician’s judgement of APD and the Delphi criteria for APD, which were developed by an international expert group, as well as the clinical burden in APD and non-APD patients and eligibility for and use of DAT were evaluated. The results for the Swiss subgroup were subsequently compared with the international full analysis set of the OBSERVE-PD study. RESULTS Based on physician’s judgement, 69.4% of patients included in the Swiss study suffered from APD. A moderate correlation between physician’s judgement and the Delphi criteria for APD was observed (Κ = 0.480, 95% confidence interval 0.317–0.642). Clinical burden was higher for APD patients, as shown by worse scores for activities of daily living, motor symptom severity, dyskinesia duration/disability, duration of “off” time, non-motor symptoms and quality of life as compared with non-APD patients (p <0.0001 for all). The Swiss data for disease burden were comparable to the international findings, except that the Swiss patients showed less “off” time. Amongst APD patients eligible for DAT, the main reason for no DAT in Switzerland was patient refusal, whereas patients needing more time to decide about it was the most frequent reason in the international analysis. CONCLUSIONS The study shows that the burden of APD in tertiary care centres in Switzerland is comparable to the international situation. Patient refusal is the main reason for no DAT amongst eligible APD patients in such centres. The identification of standard APD classification parameters and evaluation of the reasons for no DAT are relevant for optimising treatment strategies and the transition to DAT.
Collapse
Affiliation(s)
- Jens Carsten Möller
- Parkinson Center, Center for Neurological Rehabilitation, Zihlschlacht, Switzerland / Faculty of Medicine, Philipps University, Marburg, Germany
| | - Christian R Baumann
- Center for Movement and Functional Neurosurgery, Department of Neurology, University Hospital Zurich, Switzerland
| | - Pierre R Burkhard
- Department for Clinical Neuroscience, Geneva University Hospitals (HUG), Geneva, Switzerland
| | - Alain Kaelin-Lang
- Neurocenter of Southern Switzerland, Lugano, Switzerland / Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland / Faculty of Medicine, University of Berne, Switzerland
| | - Irène Küng
- AbbVie AG Switzerland, Baar, Switzerland
| | | | | |
Collapse
|
13
|
Kaelin-Lang A, You H, Burgunder JM, Lönnfors-Weitze T, Loher TJ, Taub E, Isaias IU, Krauss JK, Michael Schüpbach W. Bilateral pallidal stimulation improves cervical dystonia for more than a decade. Parkinsonism Relat Disord 2020; 81:78-81. [DOI: 10.1016/j.parkreldis.2020.10.028] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/05/2020] [Revised: 10/13/2020] [Accepted: 10/14/2020] [Indexed: 12/27/2022]
|
14
|
Vacchi E, Burrello J, Di Silvestre D, Burrello A, Bolis S, Mauri P, Vassalli G, Cereda CW, Farina C, Barile L, Kaelin-Lang A, Melli G. Immune profiling of plasma-derived extracellular vesicles identifies Parkinson disease. Neurol Neuroimmunol Neuroinflamm 2020; 7:7/6/e866. [PMID: 32817412 PMCID: PMC7428368 DOI: 10.1212/nxi.0000000000000866] [Citation(s) in RCA: 24] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/16/2019] [Accepted: 05/28/2020] [Indexed: 12/11/2022]
Abstract
Objective To develop a diagnostic model based on plasma-derived extracellular vesicle (EV) subpopulations in Parkinson disease (PD) and atypical parkinsonism (AP), we applied an innovative flow cytometric multiplex bead-based platform. Methods Plasma-derived EVs were isolated from PD, matched healthy controls, multiple system atrophy (MSA), and AP with tauopathies (AP-Tau). The expression levels of 37 EV surface markers were measured by flow cytometry and correlated with clinical scales. A diagnostic model based on EV surface markers expression was built via supervised machine learning algorithms and validated in an external cohort. Results Distinctive pools of EV surface markers related to inflammatory and immune cells stratified patients according to the clinical diagnosis. PD and MSA displayed a greater pool of overexpressed immune markers, suggesting a different immune dysregulation in PD and MSA vs AP-Tau. The receiver operating characteristic curve analysis of a compound EV marker showed optimal diagnostic performance for PD (area under the curve [AUC] 0.908; sensitivity 96.3%, specificity 78.9%) and MSA (AUC 0.974; sensitivity 100%, specificity 94.7%) and good accuracy for AP-Tau (AUC 0.718; sensitivity 77.8%, specificity 89.5%). A diagnostic model based on EV marker expression correctly classified 88.9% of patients with reliable diagnostic performance after internal and external validations. Conclusions Immune profiling of plasmatic EVs represents a crucial step toward the identification of biomarkers of disease for PD and AP.
Collapse
Affiliation(s)
- Elena Vacchi
- From the Laboratory for Biomedical Neurosciences (E.V., A.K.-L., G.M.), Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale; Faculty of Biomedical Sciences (E.V., G.V., L.B., A.K.-L., G.M.), Università della Svizzera Italiana; Cellular and Molecular Cardiology Laboratory (J.B., G.V.), Cardiocentro Ticino Foundation, Lugano, Switzerland; Proteomic and Metabolomic Laboratory (D.D.S., P.M.), Institute for Biomedical Technologies-National Research Council (ITB-CNR), Segrate (Milan), Italy; Department of Electrical (A.B.), Electronic and Information Engineering "Guglielmo Marconi" (DEI), University of Bologna, Italy; Laboratory for Cardiovascular Theranostics (S.B., L.B.), Cardiocentro Ticino Foundation, Lugano, Switzerland; Neurology Department (C.W.C., A.K.-L., G.M.), Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano; and Immunobiology of Neurological Disorders Lab (C.F.), Institute of Experimental Neurology (INSpe) and Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Jacopo Burrello
- From the Laboratory for Biomedical Neurosciences (E.V., A.K.-L., G.M.), Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale; Faculty of Biomedical Sciences (E.V., G.V., L.B., A.K.-L., G.M.), Università della Svizzera Italiana; Cellular and Molecular Cardiology Laboratory (J.B., G.V.), Cardiocentro Ticino Foundation, Lugano, Switzerland; Proteomic and Metabolomic Laboratory (D.D.S., P.M.), Institute for Biomedical Technologies-National Research Council (ITB-CNR), Segrate (Milan), Italy; Department of Electrical (A.B.), Electronic and Information Engineering "Guglielmo Marconi" (DEI), University of Bologna, Italy; Laboratory for Cardiovascular Theranostics (S.B., L.B.), Cardiocentro Ticino Foundation, Lugano, Switzerland; Neurology Department (C.W.C., A.K.-L., G.M.), Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano; and Immunobiology of Neurological Disorders Lab (C.F.), Institute of Experimental Neurology (INSpe) and Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Dario Di Silvestre
- From the Laboratory for Biomedical Neurosciences (E.V., A.K.-L., G.M.), Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale; Faculty of Biomedical Sciences (E.V., G.V., L.B., A.K.-L., G.M.), Università della Svizzera Italiana; Cellular and Molecular Cardiology Laboratory (J.B., G.V.), Cardiocentro Ticino Foundation, Lugano, Switzerland; Proteomic and Metabolomic Laboratory (D.D.S., P.M.), Institute for Biomedical Technologies-National Research Council (ITB-CNR), Segrate (Milan), Italy; Department of Electrical (A.B.), Electronic and Information Engineering "Guglielmo Marconi" (DEI), University of Bologna, Italy; Laboratory for Cardiovascular Theranostics (S.B., L.B.), Cardiocentro Ticino Foundation, Lugano, Switzerland; Neurology Department (C.W.C., A.K.-L., G.M.), Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano; and Immunobiology of Neurological Disorders Lab (C.F.), Institute of Experimental Neurology (INSpe) and Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Alessio Burrello
- From the Laboratory for Biomedical Neurosciences (E.V., A.K.-L., G.M.), Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale; Faculty of Biomedical Sciences (E.V., G.V., L.B., A.K.-L., G.M.), Università della Svizzera Italiana; Cellular and Molecular Cardiology Laboratory (J.B., G.V.), Cardiocentro Ticino Foundation, Lugano, Switzerland; Proteomic and Metabolomic Laboratory (D.D.S., P.M.), Institute for Biomedical Technologies-National Research Council (ITB-CNR), Segrate (Milan), Italy; Department of Electrical (A.B.), Electronic and Information Engineering "Guglielmo Marconi" (DEI), University of Bologna, Italy; Laboratory for Cardiovascular Theranostics (S.B., L.B.), Cardiocentro Ticino Foundation, Lugano, Switzerland; Neurology Department (C.W.C., A.K.-L., G.M.), Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano; and Immunobiology of Neurological Disorders Lab (C.F.), Institute of Experimental Neurology (INSpe) and Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Sara Bolis
- From the Laboratory for Biomedical Neurosciences (E.V., A.K.-L., G.M.), Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale; Faculty of Biomedical Sciences (E.V., G.V., L.B., A.K.-L., G.M.), Università della Svizzera Italiana; Cellular and Molecular Cardiology Laboratory (J.B., G.V.), Cardiocentro Ticino Foundation, Lugano, Switzerland; Proteomic and Metabolomic Laboratory (D.D.S., P.M.), Institute for Biomedical Technologies-National Research Council (ITB-CNR), Segrate (Milan), Italy; Department of Electrical (A.B.), Electronic and Information Engineering "Guglielmo Marconi" (DEI), University of Bologna, Italy; Laboratory for Cardiovascular Theranostics (S.B., L.B.), Cardiocentro Ticino Foundation, Lugano, Switzerland; Neurology Department (C.W.C., A.K.-L., G.M.), Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano; and Immunobiology of Neurological Disorders Lab (C.F.), Institute of Experimental Neurology (INSpe) and Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Pierluigi Mauri
- From the Laboratory for Biomedical Neurosciences (E.V., A.K.-L., G.M.), Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale; Faculty of Biomedical Sciences (E.V., G.V., L.B., A.K.-L., G.M.), Università della Svizzera Italiana; Cellular and Molecular Cardiology Laboratory (J.B., G.V.), Cardiocentro Ticino Foundation, Lugano, Switzerland; Proteomic and Metabolomic Laboratory (D.D.S., P.M.), Institute for Biomedical Technologies-National Research Council (ITB-CNR), Segrate (Milan), Italy; Department of Electrical (A.B.), Electronic and Information Engineering "Guglielmo Marconi" (DEI), University of Bologna, Italy; Laboratory for Cardiovascular Theranostics (S.B., L.B.), Cardiocentro Ticino Foundation, Lugano, Switzerland; Neurology Department (C.W.C., A.K.-L., G.M.), Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano; and Immunobiology of Neurological Disorders Lab (C.F.), Institute of Experimental Neurology (INSpe) and Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Giuseppe Vassalli
- From the Laboratory for Biomedical Neurosciences (E.V., A.K.-L., G.M.), Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale; Faculty of Biomedical Sciences (E.V., G.V., L.B., A.K.-L., G.M.), Università della Svizzera Italiana; Cellular and Molecular Cardiology Laboratory (J.B., G.V.), Cardiocentro Ticino Foundation, Lugano, Switzerland; Proteomic and Metabolomic Laboratory (D.D.S., P.M.), Institute for Biomedical Technologies-National Research Council (ITB-CNR), Segrate (Milan), Italy; Department of Electrical (A.B.), Electronic and Information Engineering "Guglielmo Marconi" (DEI), University of Bologna, Italy; Laboratory for Cardiovascular Theranostics (S.B., L.B.), Cardiocentro Ticino Foundation, Lugano, Switzerland; Neurology Department (C.W.C., A.K.-L., G.M.), Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano; and Immunobiology of Neurological Disorders Lab (C.F.), Institute of Experimental Neurology (INSpe) and Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Carlo W Cereda
- From the Laboratory for Biomedical Neurosciences (E.V., A.K.-L., G.M.), Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale; Faculty of Biomedical Sciences (E.V., G.V., L.B., A.K.-L., G.M.), Università della Svizzera Italiana; Cellular and Molecular Cardiology Laboratory (J.B., G.V.), Cardiocentro Ticino Foundation, Lugano, Switzerland; Proteomic and Metabolomic Laboratory (D.D.S., P.M.), Institute for Biomedical Technologies-National Research Council (ITB-CNR), Segrate (Milan), Italy; Department of Electrical (A.B.), Electronic and Information Engineering "Guglielmo Marconi" (DEI), University of Bologna, Italy; Laboratory for Cardiovascular Theranostics (S.B., L.B.), Cardiocentro Ticino Foundation, Lugano, Switzerland; Neurology Department (C.W.C., A.K.-L., G.M.), Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano; and Immunobiology of Neurological Disorders Lab (C.F.), Institute of Experimental Neurology (INSpe) and Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Cinthia Farina
- From the Laboratory for Biomedical Neurosciences (E.V., A.K.-L., G.M.), Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale; Faculty of Biomedical Sciences (E.V., G.V., L.B., A.K.-L., G.M.), Università della Svizzera Italiana; Cellular and Molecular Cardiology Laboratory (J.B., G.V.), Cardiocentro Ticino Foundation, Lugano, Switzerland; Proteomic and Metabolomic Laboratory (D.D.S., P.M.), Institute for Biomedical Technologies-National Research Council (ITB-CNR), Segrate (Milan), Italy; Department of Electrical (A.B.), Electronic and Information Engineering "Guglielmo Marconi" (DEI), University of Bologna, Italy; Laboratory for Cardiovascular Theranostics (S.B., L.B.), Cardiocentro Ticino Foundation, Lugano, Switzerland; Neurology Department (C.W.C., A.K.-L., G.M.), Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano; and Immunobiology of Neurological Disorders Lab (C.F.), Institute of Experimental Neurology (INSpe) and Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Lucio Barile
- From the Laboratory for Biomedical Neurosciences (E.V., A.K.-L., G.M.), Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale; Faculty of Biomedical Sciences (E.V., G.V., L.B., A.K.-L., G.M.), Università della Svizzera Italiana; Cellular and Molecular Cardiology Laboratory (J.B., G.V.), Cardiocentro Ticino Foundation, Lugano, Switzerland; Proteomic and Metabolomic Laboratory (D.D.S., P.M.), Institute for Biomedical Technologies-National Research Council (ITB-CNR), Segrate (Milan), Italy; Department of Electrical (A.B.), Electronic and Information Engineering "Guglielmo Marconi" (DEI), University of Bologna, Italy; Laboratory for Cardiovascular Theranostics (S.B., L.B.), Cardiocentro Ticino Foundation, Lugano, Switzerland; Neurology Department (C.W.C., A.K.-L., G.M.), Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano; and Immunobiology of Neurological Disorders Lab (C.F.), Institute of Experimental Neurology (INSpe) and Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Alain Kaelin-Lang
- From the Laboratory for Biomedical Neurosciences (E.V., A.K.-L., G.M.), Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale; Faculty of Biomedical Sciences (E.V., G.V., L.B., A.K.-L., G.M.), Università della Svizzera Italiana; Cellular and Molecular Cardiology Laboratory (J.B., G.V.), Cardiocentro Ticino Foundation, Lugano, Switzerland; Proteomic and Metabolomic Laboratory (D.D.S., P.M.), Institute for Biomedical Technologies-National Research Council (ITB-CNR), Segrate (Milan), Italy; Department of Electrical (A.B.), Electronic and Information Engineering "Guglielmo Marconi" (DEI), University of Bologna, Italy; Laboratory for Cardiovascular Theranostics (S.B., L.B.), Cardiocentro Ticino Foundation, Lugano, Switzerland; Neurology Department (C.W.C., A.K.-L., G.M.), Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano; and Immunobiology of Neurological Disorders Lab (C.F.), Institute of Experimental Neurology (INSpe) and Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Giorgia Melli
- From the Laboratory for Biomedical Neurosciences (E.V., A.K.-L., G.M.), Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale; Faculty of Biomedical Sciences (E.V., G.V., L.B., A.K.-L., G.M.), Università della Svizzera Italiana; Cellular and Molecular Cardiology Laboratory (J.B., G.V.), Cardiocentro Ticino Foundation, Lugano, Switzerland; Proteomic and Metabolomic Laboratory (D.D.S., P.M.), Institute for Biomedical Technologies-National Research Council (ITB-CNR), Segrate (Milan), Italy; Department of Electrical (A.B.), Electronic and Information Engineering "Guglielmo Marconi" (DEI), University of Bologna, Italy; Laboratory for Cardiovascular Theranostics (S.B., L.B.), Cardiocentro Ticino Foundation, Lugano, Switzerland; Neurology Department (C.W.C., A.K.-L., G.M.), Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano; and Immunobiology of Neurological Disorders Lab (C.F.), Institute of Experimental Neurology (INSpe) and Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy.
| |
Collapse
|
15
|
Ratti PL, Faraci F, Hackethal S, Mascheroni A, Ferlito C, Caverzasio S, Amato N, Choe EK, Luo Y, Nunes-Ferreira PE, Galati S, Puiatti A, Kaelin-Lang A. A New Prospective, Home-Based Monitoring of Motor Symptoms in Parkinson's Disease. J Parkinsons Dis 2020; 9:803-809. [PMID: 31476169 PMCID: PMC6839495 DOI: 10.3233/jpd-191662] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Background: Subjective symptoms, which are retrospectively assessed during clinical interviews in the office, may be influenced by patient recall in Parkinson’s disease (PD). Prospective collection of subjective data might be an effective tool to overcome this bias. Objective: We investigated the correspondence between prospectively and retrospectively assessed motor symptoms in PD. Methods: Forty-two consecutive patients (9 females, 67±9.8 years old) with mild to moderate PD reported their symptoms four times a day for two weeks, using the “SleepFit” application (app) for tablets. This app incorporates a new Visual Analogue Scale assessing global mobility (m-VAS), and the Scales for Outcome in Parkinson Assessment Diary Card (SCOPA-DC). At day 14, the Movement Disorders Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) parts II and IV questionnaires were completed at the hospital. Agreement (root mean square difference) and the tendency to under- or overestimate their symptoms by patients (relative difference after normalization) were calculated to compare prospectively vs. retrospectively collected information. Results: Although agreement was good for overall scores (m-VAS: 10.0%; SCOPA-DC: 18.3%), and for single motor symptoms (involuntary movements, hand dexterity, walking, changing position; each <20%), some individuals with more advanced disease, higher fatigue or worse sleep quality showed poor symptom recall in retrospect. Moreover, a subgroup of patients (16.7%) either over- or underestimated symptom severity. Conclusions: Regular, prospective monitoring of motor symptoms is suitable in PD patients. SleepFit might be a useful tool in routine practice to identify patients tending to under- or overestimate their symptoms, and for their follow-up.
Collapse
Affiliation(s)
- Pietro-Luca Ratti
- Neurocenter of Southern Switzerland, Regional Hospital of Lugano, Lugano, Switzerland.,Clinical Neurophysiology Unit, Department of Neurology, Pierre Zobda-Quitman Hospital, University Hospitals of Martinique, Fort-de-France, Martinique, France
| | - Francesca Faraci
- Institute of Information Technology and Networking, University of Applied Sciences and Arts of Southern Switzerland (SUPSI) - Galleria 2, Manno, Switzerland
| | - Sandra Hackethal
- Neurocenter of Southern Switzerland, Regional Hospital of Lugano, Lugano, Switzerland
| | - Alessandro Mascheroni
- Institute of Information Technology and Networking, University of Applied Sciences and Arts of Southern Switzerland (SUPSI) - Galleria 2, Manno, Switzerland
| | - Clara Ferlito
- Neurocenter of Southern Switzerland, Regional Hospital of Lugano, Lugano, Switzerland
| | - Serena Caverzasio
- Neurocenter of Southern Switzerland, Regional Hospital of Lugano, Lugano, Switzerland
| | - Ninfa Amato
- Neurocenter of Southern Switzerland, Regional Hospital of Lugano, Lugano, Switzerland
| | - Eun Kyoung Choe
- College of Information Studies, University of Maryland, College Park, MD, USA
| | - Yuhan Luo
- College of Information Studies, University of Maryland, College Park, MD, USA
| | | | - Salvatore Galati
- Neurocenter of Southern Switzerland, Regional Hospital of Lugano, Lugano, Switzerland
| | - Alessandro Puiatti
- Institute of Information Technology and Networking, University of Applied Sciences and Arts of Southern Switzerland (SUPSI) - Galleria 2, Manno, Switzerland
| | - Alain Kaelin-Lang
- Neurocenter of Southern Switzerland, Regional Hospital of Lugano, Lugano, Switzerland.,Faculty of Biomedical Sciences, University of Southern Switzerland, Lugano, Switzerland.,Medical faculty, University of Bern, Switzerland
| |
Collapse
|
16
|
Di Giovanni G, Grandi LC, Fedele E, Orban G, Salvadè A, Song W, Cuboni E, Stefani A, Kaelin-Lang A, Galati S. Acute and Chronic Dopaminergic Depletion Differently Affect Motor Thalamic Function. Int J Mol Sci 2020; 21:ijms21082734. [PMID: 32326424 PMCID: PMC7215393 DOI: 10.3390/ijms21082734] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2020] [Revised: 04/09/2020] [Accepted: 04/12/2020] [Indexed: 12/23/2022] Open
Abstract
The motor thalamus (MTh) plays a crucial role in the basal ganglia (BG)-cortical loop in motor information codification. Despite this, there is limited evidence of MTh functionality in normal and Parkinsonian conditions. To shed light on the functional properties of the MTh, we examined the effects of acute and chronic dopamine (DA) depletion on the neuronal firing of MTh neurons, cortical/MTh interplay and MTh extracellular concentrations of glutamate (GLU) and gamma-aminobutyric acid (GABA) in two states of DA depletion: acute depletion induced by the tetrodotoxin (TTX) and chronic denervation obtained by 6-hydroxydopamine (6-OHDA), both infused into the medial forebrain bundle (MFB) in anesthetized rats. The acute TTX DA depletion caused a clear-cut reduction in MTh neuronal activity without changes in burst content, whereas the chronic 6-OHDA depletion did not modify the firing rate but increased the burst firing. The phase correlation analysis underscored that the 6-OHDA chronic DA depletion affected the MTh-cortical activity coupling compared to the acute TTX-induced DA depletion state. The TTX acute DA depletion caused a clear-cut increase of the MTh GABA concentration and no change of GLU levels. On the other hand, the 6-OHDA-induced chronic DA depletion led to a significant reduction of local GABA and an increase of GLU levels in the MTh. These data show that MTh is affected by DA depletion and support the hypothesis that a rebalancing of MTh in the chronic condition counterbalances the profound alteration arising after acute DA depletion state.
Collapse
Affiliation(s)
- Giuseppe Di Giovanni
- Laboratory of Neurophysiology, Department of Physiology and Biochemistry, Faculty of Medicine and Surgery, University of Malta, Msida MSD 2080, Malta
- Neuroscience Division, School of Biosciences, Cardiff University, Cardiff CF10 3AX, UK
| | - Laura Clara Grandi
- Laboratory for Biomedical Neurosciences, Neurocenter of Southern Switzerland, 6900 Taverne, Switzerland
| | - Ernesto Fedele
- Section of Pharmacology and Toxicology, Department of Pharmacy, Center of Excellence for Biomedical Research, University of Genoa, 16148 Genoa, Italy
- IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy
| | - Gergely Orban
- Laboratory for Biomedical Neurosciences, Neurocenter of Southern Switzerland, 6900 Taverne, Switzerland
| | - Agnese Salvadè
- Laboratory for Biomedical Neurosciences, Neurocenter of Southern Switzerland, 6900 Taverne, Switzerland
| | - Wei Song
- Laboratory for Biomedical Neurosciences, Neurocenter of Southern Switzerland, 6900 Taverne, Switzerland
| | - Eleonora Cuboni
- Laboratory of Neurophysiology, Department of Physiology and Biochemistry, Faculty of Medicine and Surgery, University of Malta, Msida MSD 2080, Malta
| | - Alessandro Stefani
- Department of system medicine, Faculty of Medicine and Surgery, University of Rome "Tor Vergata", 00133 Rome, Italy
| | - Alain Kaelin-Lang
- Laboratory for Biomedical Neurosciences, Neurocenter of Southern Switzerland, 6900 Taverne, Switzerland
- Medical Faculty, University of Bern, 3008 Bern, Switzerland
- Faculty of Biomedical Sciences, Università della Svizzera Italiana, 6900 Lugano, Switzerland
| | - Salvatore Galati
- Laboratory for Biomedical Neurosciences, Neurocenter of Southern Switzerland, 6900 Taverne, Switzerland
- Faculty of Biomedical Sciences, Università della Svizzera Italiana, 6900 Lugano, Switzerland
- Center for Movement Disorders, Neurocenter of Southern Switzerland, 6900 Lugano, Switzerland
| |
Collapse
|
17
|
Piffaretti D, Burgio F, Thelen M, Kaelin-Lang A, Paganetti P, Reinert M, D'Angelo ML. Corrigendum to "Protoporphyrin IX tracer fluorescence modulation for improved brain tumor cell lines visualization". J Photochem Photobiol B 2020; 205:111828. [PMID: 32163836 DOI: 10.1016/j.jphotobiol.2020.111828] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
Fluorescence image guided surgical resection (FIGR) of high grade gliomas (HGGs) takes advantage of the accumulation of the tracer protoporphyrin IX (PpIX) in glioma cells following administration of 5-aminolevulinic acid (5-ALA). Occasionally, PpIX fluorescence intensity may be insufficient, thus compromising the efficacy and precision of the surgical intervention. The cause for the signal variation is unclear and strategies to improve the intensity of PpIX fluorescence are considered necessary. We have previously shown that differential expression of the epidermal growth factor receptor in glioblastoma cells affects PpIX fluorescence. Herein, we investigated other factors impairing PpIX accumulation and pharmacological treatments able to enhance PpIX fluorescence in glioblastoma cells displaying lower signal. In the present study we demonstrate that presence of serum in cell culture medium and differences in cellular confluence can negatively influence PpIX accumulation in U87 cell lines. We hypothesized that PpIX fluorescence intensity results from the interplay between the metabolic clearance of PpIX mediated by ferrochelatase (FECH) and heme oxygenase-1 (HO-1) and the cellular efflux of PpIX through the ATP-binding cassette subfamily G member 2 (ABCG2). Based on the availability of compounds targeting these proteins and inhibiting them, in this study we used modulators such as genistein, an isoflavone able to inhibit ABCG2; deferoxamine, which chelate iron ions impairing FECH activity and tin protoporphyrin IX (SnPP), the specific HO-1 inhibitor. Finally, we showed the efficacy of a precisely tuned pharmacological treatment in increasing PpIX accumulation and consequently fluorescence in glioblastoma cells. This strategy may translate in more sensitive tracing of tumor cells in-vivo and improved FIGR of HGGs and possibly low grade gliomas (LGGs).
Collapse
Affiliation(s)
- Deborah Piffaretti
- Laboratory for Biomedical Neurosciences, Neurocenter of Southern Switzerland, Ente Cantonale Ospedaliero, Torricella-Taverne, Switzerland; Faculty of Medicine, Graduate School for Cellular and Biomedical Sciences, University of Bern, Bern, Switzerland
| | - Floriana Burgio
- Laboratory for Biomedical Neurosciences, Neurocenter of Southern Switzerland, Ente Cantonale Ospedaliero, Torricella-Taverne, Switzerland; Fachhochschule Nordwestschweiz (FHNW), Muttenz, Basel, Switzerland
| | - Marcus Thelen
- Institute for Research in Biomedicine (IRB), Università della Svizzera Italiana, Bellinzona, Switzerland
| | - Alain Kaelin-Lang
- Laboratory for Biomedical Neurosciences, Neurocenter of Southern Switzerland, Ente Cantonale Ospedaliero, Torricella-Taverne, Switzerland; Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland; Faculty of Biomedical Neurosciences, Università della Svizzera Italiana, Lugano, Switzerland
| | - Paolo Paganetti
- Laboratory for Biomedical Neurosciences, Neurocenter of Southern Switzerland, Ente Cantonale Ospedaliero, Torricella-Taverne, Switzerland
| | - Michael Reinert
- Laboratory for Biomedical Neurosciences, Neurocenter of Southern Switzerland, Ente Cantonale Ospedaliero, Torricella-Taverne, Switzerland; Department of Neurosurgery, Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland; Department of Neurosurgery, Inselspital Bern, University of Bern, Bern, Switzerland.
| | - Maria Luisa D'Angelo
- Laboratory for Biomedical Neurosciences, Neurocenter of Southern Switzerland, Ente Cantonale Ospedaliero, Torricella-Taverne, Switzerland
| |
Collapse
|
18
|
Gennaro F, Maino P, Kaelin-Lang A, De Bock K, de Bruin ED. Corticospinal Control of Human Locomotion as a New Determinant of Age-Related Sarcopenia: An Exploratory Study. J Clin Med 2020; 9:E720. [PMID: 32155951 PMCID: PMC7141202 DOI: 10.3390/jcm9030720] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2020] [Revised: 02/25/2020] [Accepted: 03/02/2020] [Indexed: 12/11/2022] Open
Abstract
Sarcopenia is a muscle disease listed within the ICD-10 classification. Several operational definitions have been created for sarcopenia screening; however, an international consensus is lacking. The Centers for Disease Control and Prevention have recently recognized that sarcopenia detection requires improved diagnosis and screening measures. Mounting evidence hints towards changes in the corticospinal communication system where corticomuscular coherence (CMC) reflects an effective mechanism of corticospinal interaction. CMC can be assessed during locomotion by means of simultaneously measuring Electroencephalography (EEG) and Electromyography (EMG). The aim of this study was to perform sarcopenia screening in community-dwelling older adults and explore the possibility of using CMC assessed during gait to discriminate between sarcopenic and non-sarcopenic older adults. Receiver Operating Characteristic (ROC) curves showed high sensitivity, precision and accuracy of CMC assessed from EEG Cz sensor and EMG sensors located over Musculus Vastus Medialis [Cz-VM; AUC (95.0%CI): 0.98 (0.92-1.04), sensitivity: 1.00, 1-specificity: 0.89, p < 0.001] and with Musculus Biceps Femoris [Cz-BF; AUC (95.0%CI): 0.86 (0.68-1.03), sensitivity: 1.00, 1-specificity: 0.70, p < 0.001]. These muscles showed significant differences with large magnitude of effect between sarcopenic and non-sarcopenic older adults [Hedge's g (95.0%CI): 2.2 (1.3-3.1), p = 0.005 and Hedge's g (95.0%CI): 1.5 (0.7-2.2), p = 0.010; respectively]. The novelty of this exploratory investigation is the hint toward a novel possible determinant of age-related sarcopenia, derived from corticospinal control of locomotion and shown by the observed large differences in CMC when sarcopenic and non-sarcopenic older adults are compared. This, in turn, might represent in future a potential treatment target to counteract sarcopenia as well as a parameter to monitor the progression of the disease and/or the potential recovery following other treatment interventions.
Collapse
Affiliation(s)
- Federico Gennaro
- Department of Health Sciences and Technology, Institute of Human Movement Sciences and Sport, ETH Zurich, 8093 Zurich, Switzerland; (K.D.B.); (E.D.d.B.)
| | - Paolo Maino
- Pain Management Center, Neurocenter of Southern Switzerland, Regional Hospital of Lugano, 6962 Lugano, Switzerland;
| | - Alain Kaelin-Lang
- Neurocenter of Southern Switzerland, Regional Hospital of Lugano, 6900 Lugano, Switzerland;
- Faculty of Biomedical Sciences, Università della Svizzera Italiana, 6900 Lugano, Switzerland
- Medical faculty, University of Bern, 3008 Bern, Switzerland
| | - Katrien De Bock
- Department of Health Sciences and Technology, Institute of Human Movement Sciences and Sport, ETH Zurich, 8093 Zurich, Switzerland; (K.D.B.); (E.D.d.B.)
| | - Eling D. de Bruin
- Department of Health Sciences and Technology, Institute of Human Movement Sciences and Sport, ETH Zurich, 8093 Zurich, Switzerland; (K.D.B.); (E.D.d.B.)
- Department of Neurobiology, Division of Physiotherapy, Care Sciences and Society, Karolinska Institutet, 171 77 Stockholm, Sweden
| |
Collapse
|
19
|
Ripellino P, Pasi E, Melli G, Staedler C, Fraga M, Moradpour D, Sahli R, Aubert V, Martinetti G, Bihl F, Bernasconi E, Terziroli Beretta-Piccoli B, Cerny A, Dalton HR, Zehnder C, Mathis B, Zecca C, Disanto G, Kaelin-Lang A, Gobbi C. Neurologic complications of acute hepatitis E virus infection. Neurol Neuroimmunol Neuroinflamm 2019; 7:7/1/e643. [PMID: 31806684 PMCID: PMC6935854 DOI: 10.1212/nxi.0000000000000643] [Citation(s) in RCA: 30] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/16/2019] [Accepted: 10/11/2019] [Indexed: 02/06/2023]
Abstract
Objective To assess the prevalence and clinical features of neurologic involvement in patients with acute hepatitis E virus (HEV) infection in Southern Switzerland. Methods Among 1,940 consecutive patients investigated for acute hepatitis E, we identified 141 cases of acute of HEV infection (anti-HEV immunoglobulin M and immunoglobulin G both reactive and/or HEV RNA positive) between June 2014 and September 2017. Neurologic cases were followed up for 6 months. We compared patients with and without neurologic symptoms. Results Neurologic symptoms occurred in 43 acute HEV cases (30.4%) and consisted of neuralgic amyotrophy (NA, n = 15, 10.6%) and myalgia (n = 28, 19.8%). All NA cases were immunocompetent. Men had higher odds (OR = 5.2, CI 1.12–24.0, p = 0.03) of developing NA after infection with HEV, and in 3 couples simultaneously infected with HEV, only men developed NA. Bilateral involvement of NA was predominant (2:1) and occurred only in men. Seven NA cases were viremic (all genotype 3), but HEV was undetectable in their CSF. In the acute phase of NA, 9 patients were treated with intravenous immunoglobulin and 4 with prednisone, reporting no side effects and improvement in pain and strength. Myalgia occurred both without (n = 16) or with (n = 12) concomitant elevated serum creatinine kinase. Seven cases with myalgia in the shoulder girdle did not have muscle weakness (“forme fruste” of NA). Conclusions Neurologic symptoms occurred in one-third of acute HEV infections and consisted of NA and myalgia. NA seems to occur more frequently in men infected by HEV and has a predominant (but not exclusive) bilateral involvement.
Collapse
Affiliation(s)
- Paolo Ripellino
- From the Department of Neurology (P.R., G.M., C.S., C.Z., G.D., A.K.-L., C.G.), Neurocenter of Southern Switzerland, Lugano, CH; Laboratory of Microbiology EOLAB (E.P., G.M.), Bellinzona, CH; Faculty of Biomedical Sciences, USI (G.M., C.Z., A.K.-L., C.G.), Lugano, CH; Division of Gastroenterology and Hepatology, Lausanne University Hospital (M.F., D.M.), Lausanne, CH; Institute of Microbiology, Lausanne University Hospital (R.S.), Lausanne, CH; Laboratory of Immunology, Lausanne University Hospital (V.A.), CH; Department of Hepatology, Hospital of Bellinzona (F.B.), CH; Division of Infectious Diseases (E.B.), Hospital of Lugano, CH; Epatocentro Ticino (B.T.B.-P., A.C.), Lugano, CH; Queens Park (H.R.D.), London, UK; Synlab Ticino (C.Z.), Bioggio, CH; and Unilabs Ticino (B.M.), Lugano, CH.
| | - Emanuela Pasi
- From the Department of Neurology (P.R., G.M., C.S., C.Z., G.D., A.K.-L., C.G.), Neurocenter of Southern Switzerland, Lugano, CH; Laboratory of Microbiology EOLAB (E.P., G.M.), Bellinzona, CH; Faculty of Biomedical Sciences, USI (G.M., C.Z., A.K.-L., C.G.), Lugano, CH; Division of Gastroenterology and Hepatology, Lausanne University Hospital (M.F., D.M.), Lausanne, CH; Institute of Microbiology, Lausanne University Hospital (R.S.), Lausanne, CH; Laboratory of Immunology, Lausanne University Hospital (V.A.), CH; Department of Hepatology, Hospital of Bellinzona (F.B.), CH; Division of Infectious Diseases (E.B.), Hospital of Lugano, CH; Epatocentro Ticino (B.T.B.-P., A.C.), Lugano, CH; Queens Park (H.R.D.), London, UK; Synlab Ticino (C.Z.), Bioggio, CH; and Unilabs Ticino (B.M.), Lugano, CH
| | - Giorgia Melli
- From the Department of Neurology (P.R., G.M., C.S., C.Z., G.D., A.K.-L., C.G.), Neurocenter of Southern Switzerland, Lugano, CH; Laboratory of Microbiology EOLAB (E.P., G.M.), Bellinzona, CH; Faculty of Biomedical Sciences, USI (G.M., C.Z., A.K.-L., C.G.), Lugano, CH; Division of Gastroenterology and Hepatology, Lausanne University Hospital (M.F., D.M.), Lausanne, CH; Institute of Microbiology, Lausanne University Hospital (R.S.), Lausanne, CH; Laboratory of Immunology, Lausanne University Hospital (V.A.), CH; Department of Hepatology, Hospital of Bellinzona (F.B.), CH; Division of Infectious Diseases (E.B.), Hospital of Lugano, CH; Epatocentro Ticino (B.T.B.-P., A.C.), Lugano, CH; Queens Park (H.R.D.), London, UK; Synlab Ticino (C.Z.), Bioggio, CH; and Unilabs Ticino (B.M.), Lugano, CH
| | - Claudio Staedler
- From the Department of Neurology (P.R., G.M., C.S., C.Z., G.D., A.K.-L., C.G.), Neurocenter of Southern Switzerland, Lugano, CH; Laboratory of Microbiology EOLAB (E.P., G.M.), Bellinzona, CH; Faculty of Biomedical Sciences, USI (G.M., C.Z., A.K.-L., C.G.), Lugano, CH; Division of Gastroenterology and Hepatology, Lausanne University Hospital (M.F., D.M.), Lausanne, CH; Institute of Microbiology, Lausanne University Hospital (R.S.), Lausanne, CH; Laboratory of Immunology, Lausanne University Hospital (V.A.), CH; Department of Hepatology, Hospital of Bellinzona (F.B.), CH; Division of Infectious Diseases (E.B.), Hospital of Lugano, CH; Epatocentro Ticino (B.T.B.-P., A.C.), Lugano, CH; Queens Park (H.R.D.), London, UK; Synlab Ticino (C.Z.), Bioggio, CH; and Unilabs Ticino (B.M.), Lugano, CH
| | - Monserrat Fraga
- From the Department of Neurology (P.R., G.M., C.S., C.Z., G.D., A.K.-L., C.G.), Neurocenter of Southern Switzerland, Lugano, CH; Laboratory of Microbiology EOLAB (E.P., G.M.), Bellinzona, CH; Faculty of Biomedical Sciences, USI (G.M., C.Z., A.K.-L., C.G.), Lugano, CH; Division of Gastroenterology and Hepatology, Lausanne University Hospital (M.F., D.M.), Lausanne, CH; Institute of Microbiology, Lausanne University Hospital (R.S.), Lausanne, CH; Laboratory of Immunology, Lausanne University Hospital (V.A.), CH; Department of Hepatology, Hospital of Bellinzona (F.B.), CH; Division of Infectious Diseases (E.B.), Hospital of Lugano, CH; Epatocentro Ticino (B.T.B.-P., A.C.), Lugano, CH; Queens Park (H.R.D.), London, UK; Synlab Ticino (C.Z.), Bioggio, CH; and Unilabs Ticino (B.M.), Lugano, CH
| | - Darius Moradpour
- From the Department of Neurology (P.R., G.M., C.S., C.Z., G.D., A.K.-L., C.G.), Neurocenter of Southern Switzerland, Lugano, CH; Laboratory of Microbiology EOLAB (E.P., G.M.), Bellinzona, CH; Faculty of Biomedical Sciences, USI (G.M., C.Z., A.K.-L., C.G.), Lugano, CH; Division of Gastroenterology and Hepatology, Lausanne University Hospital (M.F., D.M.), Lausanne, CH; Institute of Microbiology, Lausanne University Hospital (R.S.), Lausanne, CH; Laboratory of Immunology, Lausanne University Hospital (V.A.), CH; Department of Hepatology, Hospital of Bellinzona (F.B.), CH; Division of Infectious Diseases (E.B.), Hospital of Lugano, CH; Epatocentro Ticino (B.T.B.-P., A.C.), Lugano, CH; Queens Park (H.R.D.), London, UK; Synlab Ticino (C.Z.), Bioggio, CH; and Unilabs Ticino (B.M.), Lugano, CH
| | - Roland Sahli
- From the Department of Neurology (P.R., G.M., C.S., C.Z., G.D., A.K.-L., C.G.), Neurocenter of Southern Switzerland, Lugano, CH; Laboratory of Microbiology EOLAB (E.P., G.M.), Bellinzona, CH; Faculty of Biomedical Sciences, USI (G.M., C.Z., A.K.-L., C.G.), Lugano, CH; Division of Gastroenterology and Hepatology, Lausanne University Hospital (M.F., D.M.), Lausanne, CH; Institute of Microbiology, Lausanne University Hospital (R.S.), Lausanne, CH; Laboratory of Immunology, Lausanne University Hospital (V.A.), CH; Department of Hepatology, Hospital of Bellinzona (F.B.), CH; Division of Infectious Diseases (E.B.), Hospital of Lugano, CH; Epatocentro Ticino (B.T.B.-P., A.C.), Lugano, CH; Queens Park (H.R.D.), London, UK; Synlab Ticino (C.Z.), Bioggio, CH; and Unilabs Ticino (B.M.), Lugano, CH
| | - Vincent Aubert
- From the Department of Neurology (P.R., G.M., C.S., C.Z., G.D., A.K.-L., C.G.), Neurocenter of Southern Switzerland, Lugano, CH; Laboratory of Microbiology EOLAB (E.P., G.M.), Bellinzona, CH; Faculty of Biomedical Sciences, USI (G.M., C.Z., A.K.-L., C.G.), Lugano, CH; Division of Gastroenterology and Hepatology, Lausanne University Hospital (M.F., D.M.), Lausanne, CH; Institute of Microbiology, Lausanne University Hospital (R.S.), Lausanne, CH; Laboratory of Immunology, Lausanne University Hospital (V.A.), CH; Department of Hepatology, Hospital of Bellinzona (F.B.), CH; Division of Infectious Diseases (E.B.), Hospital of Lugano, CH; Epatocentro Ticino (B.T.B.-P., A.C.), Lugano, CH; Queens Park (H.R.D.), London, UK; Synlab Ticino (C.Z.), Bioggio, CH; and Unilabs Ticino (B.M.), Lugano, CH
| | - Gladys Martinetti
- From the Department of Neurology (P.R., G.M., C.S., C.Z., G.D., A.K.-L., C.G.), Neurocenter of Southern Switzerland, Lugano, CH; Laboratory of Microbiology EOLAB (E.P., G.M.), Bellinzona, CH; Faculty of Biomedical Sciences, USI (G.M., C.Z., A.K.-L., C.G.), Lugano, CH; Division of Gastroenterology and Hepatology, Lausanne University Hospital (M.F., D.M.), Lausanne, CH; Institute of Microbiology, Lausanne University Hospital (R.S.), Lausanne, CH; Laboratory of Immunology, Lausanne University Hospital (V.A.), CH; Department of Hepatology, Hospital of Bellinzona (F.B.), CH; Division of Infectious Diseases (E.B.), Hospital of Lugano, CH; Epatocentro Ticino (B.T.B.-P., A.C.), Lugano, CH; Queens Park (H.R.D.), London, UK; Synlab Ticino (C.Z.), Bioggio, CH; and Unilabs Ticino (B.M.), Lugano, CH
| | - Florian Bihl
- From the Department of Neurology (P.R., G.M., C.S., C.Z., G.D., A.K.-L., C.G.), Neurocenter of Southern Switzerland, Lugano, CH; Laboratory of Microbiology EOLAB (E.P., G.M.), Bellinzona, CH; Faculty of Biomedical Sciences, USI (G.M., C.Z., A.K.-L., C.G.), Lugano, CH; Division of Gastroenterology and Hepatology, Lausanne University Hospital (M.F., D.M.), Lausanne, CH; Institute of Microbiology, Lausanne University Hospital (R.S.), Lausanne, CH; Laboratory of Immunology, Lausanne University Hospital (V.A.), CH; Department of Hepatology, Hospital of Bellinzona (F.B.), CH; Division of Infectious Diseases (E.B.), Hospital of Lugano, CH; Epatocentro Ticino (B.T.B.-P., A.C.), Lugano, CH; Queens Park (H.R.D.), London, UK; Synlab Ticino (C.Z.), Bioggio, CH; and Unilabs Ticino (B.M.), Lugano, CH
| | - Enos Bernasconi
- From the Department of Neurology (P.R., G.M., C.S., C.Z., G.D., A.K.-L., C.G.), Neurocenter of Southern Switzerland, Lugano, CH; Laboratory of Microbiology EOLAB (E.P., G.M.), Bellinzona, CH; Faculty of Biomedical Sciences, USI (G.M., C.Z., A.K.-L., C.G.), Lugano, CH; Division of Gastroenterology and Hepatology, Lausanne University Hospital (M.F., D.M.), Lausanne, CH; Institute of Microbiology, Lausanne University Hospital (R.S.), Lausanne, CH; Laboratory of Immunology, Lausanne University Hospital (V.A.), CH; Department of Hepatology, Hospital of Bellinzona (F.B.), CH; Division of Infectious Diseases (E.B.), Hospital of Lugano, CH; Epatocentro Ticino (B.T.B.-P., A.C.), Lugano, CH; Queens Park (H.R.D.), London, UK; Synlab Ticino (C.Z.), Bioggio, CH; and Unilabs Ticino (B.M.), Lugano, CH
| | - Benedetta Terziroli Beretta-Piccoli
- From the Department of Neurology (P.R., G.M., C.S., C.Z., G.D., A.K.-L., C.G.), Neurocenter of Southern Switzerland, Lugano, CH; Laboratory of Microbiology EOLAB (E.P., G.M.), Bellinzona, CH; Faculty of Biomedical Sciences, USI (G.M., C.Z., A.K.-L., C.G.), Lugano, CH; Division of Gastroenterology and Hepatology, Lausanne University Hospital (M.F., D.M.), Lausanne, CH; Institute of Microbiology, Lausanne University Hospital (R.S.), Lausanne, CH; Laboratory of Immunology, Lausanne University Hospital (V.A.), CH; Department of Hepatology, Hospital of Bellinzona (F.B.), CH; Division of Infectious Diseases (E.B.), Hospital of Lugano, CH; Epatocentro Ticino (B.T.B.-P., A.C.), Lugano, CH; Queens Park (H.R.D.), London, UK; Synlab Ticino (C.Z.), Bioggio, CH; and Unilabs Ticino (B.M.), Lugano, CH
| | - Andreas Cerny
- From the Department of Neurology (P.R., G.M., C.S., C.Z., G.D., A.K.-L., C.G.), Neurocenter of Southern Switzerland, Lugano, CH; Laboratory of Microbiology EOLAB (E.P., G.M.), Bellinzona, CH; Faculty of Biomedical Sciences, USI (G.M., C.Z., A.K.-L., C.G.), Lugano, CH; Division of Gastroenterology and Hepatology, Lausanne University Hospital (M.F., D.M.), Lausanne, CH; Institute of Microbiology, Lausanne University Hospital (R.S.), Lausanne, CH; Laboratory of Immunology, Lausanne University Hospital (V.A.), CH; Department of Hepatology, Hospital of Bellinzona (F.B.), CH; Division of Infectious Diseases (E.B.), Hospital of Lugano, CH; Epatocentro Ticino (B.T.B.-P., A.C.), Lugano, CH; Queens Park (H.R.D.), London, UK; Synlab Ticino (C.Z.), Bioggio, CH; and Unilabs Ticino (B.M.), Lugano, CH
| | - Harry Roland Dalton
- From the Department of Neurology (P.R., G.M., C.S., C.Z., G.D., A.K.-L., C.G.), Neurocenter of Southern Switzerland, Lugano, CH; Laboratory of Microbiology EOLAB (E.P., G.M.), Bellinzona, CH; Faculty of Biomedical Sciences, USI (G.M., C.Z., A.K.-L., C.G.), Lugano, CH; Division of Gastroenterology and Hepatology, Lausanne University Hospital (M.F., D.M.), Lausanne, CH; Institute of Microbiology, Lausanne University Hospital (R.S.), Lausanne, CH; Laboratory of Immunology, Lausanne University Hospital (V.A.), CH; Department of Hepatology, Hospital of Bellinzona (F.B.), CH; Division of Infectious Diseases (E.B.), Hospital of Lugano, CH; Epatocentro Ticino (B.T.B.-P., A.C.), Lugano, CH; Queens Park (H.R.D.), London, UK; Synlab Ticino (C.Z.), Bioggio, CH; and Unilabs Ticino (B.M.), Lugano, CH
| | - Cinzia Zehnder
- From the Department of Neurology (P.R., G.M., C.S., C.Z., G.D., A.K.-L., C.G.), Neurocenter of Southern Switzerland, Lugano, CH; Laboratory of Microbiology EOLAB (E.P., G.M.), Bellinzona, CH; Faculty of Biomedical Sciences, USI (G.M., C.Z., A.K.-L., C.G.), Lugano, CH; Division of Gastroenterology and Hepatology, Lausanne University Hospital (M.F., D.M.), Lausanne, CH; Institute of Microbiology, Lausanne University Hospital (R.S.), Lausanne, CH; Laboratory of Immunology, Lausanne University Hospital (V.A.), CH; Department of Hepatology, Hospital of Bellinzona (F.B.), CH; Division of Infectious Diseases (E.B.), Hospital of Lugano, CH; Epatocentro Ticino (B.T.B.-P., A.C.), Lugano, CH; Queens Park (H.R.D.), London, UK; Synlab Ticino (C.Z.), Bioggio, CH; and Unilabs Ticino (B.M.), Lugano, CH
| | - Barbara Mathis
- From the Department of Neurology (P.R., G.M., C.S., C.Z., G.D., A.K.-L., C.G.), Neurocenter of Southern Switzerland, Lugano, CH; Laboratory of Microbiology EOLAB (E.P., G.M.), Bellinzona, CH; Faculty of Biomedical Sciences, USI (G.M., C.Z., A.K.-L., C.G.), Lugano, CH; Division of Gastroenterology and Hepatology, Lausanne University Hospital (M.F., D.M.), Lausanne, CH; Institute of Microbiology, Lausanne University Hospital (R.S.), Lausanne, CH; Laboratory of Immunology, Lausanne University Hospital (V.A.), CH; Department of Hepatology, Hospital of Bellinzona (F.B.), CH; Division of Infectious Diseases (E.B.), Hospital of Lugano, CH; Epatocentro Ticino (B.T.B.-P., A.C.), Lugano, CH; Queens Park (H.R.D.), London, UK; Synlab Ticino (C.Z.), Bioggio, CH; and Unilabs Ticino (B.M.), Lugano, CH
| | - Chiara Zecca
- From the Department of Neurology (P.R., G.M., C.S., C.Z., G.D., A.K.-L., C.G.), Neurocenter of Southern Switzerland, Lugano, CH; Laboratory of Microbiology EOLAB (E.P., G.M.), Bellinzona, CH; Faculty of Biomedical Sciences, USI (G.M., C.Z., A.K.-L., C.G.), Lugano, CH; Division of Gastroenterology and Hepatology, Lausanne University Hospital (M.F., D.M.), Lausanne, CH; Institute of Microbiology, Lausanne University Hospital (R.S.), Lausanne, CH; Laboratory of Immunology, Lausanne University Hospital (V.A.), CH; Department of Hepatology, Hospital of Bellinzona (F.B.), CH; Division of Infectious Diseases (E.B.), Hospital of Lugano, CH; Epatocentro Ticino (B.T.B.-P., A.C.), Lugano, CH; Queens Park (H.R.D.), London, UK; Synlab Ticino (C.Z.), Bioggio, CH; and Unilabs Ticino (B.M.), Lugano, CH
| | - Giulio Disanto
- From the Department of Neurology (P.R., G.M., C.S., C.Z., G.D., A.K.-L., C.G.), Neurocenter of Southern Switzerland, Lugano, CH; Laboratory of Microbiology EOLAB (E.P., G.M.), Bellinzona, CH; Faculty of Biomedical Sciences, USI (G.M., C.Z., A.K.-L., C.G.), Lugano, CH; Division of Gastroenterology and Hepatology, Lausanne University Hospital (M.F., D.M.), Lausanne, CH; Institute of Microbiology, Lausanne University Hospital (R.S.), Lausanne, CH; Laboratory of Immunology, Lausanne University Hospital (V.A.), CH; Department of Hepatology, Hospital of Bellinzona (F.B.), CH; Division of Infectious Diseases (E.B.), Hospital of Lugano, CH; Epatocentro Ticino (B.T.B.-P., A.C.), Lugano, CH; Queens Park (H.R.D.), London, UK; Synlab Ticino (C.Z.), Bioggio, CH; and Unilabs Ticino (B.M.), Lugano, CH
| | - Alain Kaelin-Lang
- From the Department of Neurology (P.R., G.M., C.S., C.Z., G.D., A.K.-L., C.G.), Neurocenter of Southern Switzerland, Lugano, CH; Laboratory of Microbiology EOLAB (E.P., G.M.), Bellinzona, CH; Faculty of Biomedical Sciences, USI (G.M., C.Z., A.K.-L., C.G.), Lugano, CH; Division of Gastroenterology and Hepatology, Lausanne University Hospital (M.F., D.M.), Lausanne, CH; Institute of Microbiology, Lausanne University Hospital (R.S.), Lausanne, CH; Laboratory of Immunology, Lausanne University Hospital (V.A.), CH; Department of Hepatology, Hospital of Bellinzona (F.B.), CH; Division of Infectious Diseases (E.B.), Hospital of Lugano, CH; Epatocentro Ticino (B.T.B.-P., A.C.), Lugano, CH; Queens Park (H.R.D.), London, UK; Synlab Ticino (C.Z.), Bioggio, CH; and Unilabs Ticino (B.M.), Lugano, CH
| | - Claudio Gobbi
- From the Department of Neurology (P.R., G.M., C.S., C.Z., G.D., A.K.-L., C.G.), Neurocenter of Southern Switzerland, Lugano, CH; Laboratory of Microbiology EOLAB (E.P., G.M.), Bellinzona, CH; Faculty of Biomedical Sciences, USI (G.M., C.Z., A.K.-L., C.G.), Lugano, CH; Division of Gastroenterology and Hepatology, Lausanne University Hospital (M.F., D.M.), Lausanne, CH; Institute of Microbiology, Lausanne University Hospital (R.S.), Lausanne, CH; Laboratory of Immunology, Lausanne University Hospital (V.A.), CH; Department of Hepatology, Hospital of Bellinzona (F.B.), CH; Division of Infectious Diseases (E.B.), Hospital of Lugano, CH; Epatocentro Ticino (B.T.B.-P., A.C.), Lugano, CH; Queens Park (H.R.D.), London, UK; Synlab Ticino (C.Z.), Bioggio, CH; and Unilabs Ticino (B.M.), Lugano, CH
| |
Collapse
|
20
|
Piffaretti D, Burgio F, Thelen M, Kaelin-Lang A, Paganetti P, Reinert M, D'Angelo ML. Protoporphyrin IX tracer fluorescence modulation for improved brain tumor cell lines visualization. J Photochem Photobiol B 2019; 201:111640. [PMID: 31734545 DOI: 10.1016/j.jphotobiol.2019.111640] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/25/2019] [Revised: 08/02/2019] [Accepted: 09/24/2019] [Indexed: 01/31/2023]
Abstract
Fluorescence image guided surgical resection (FIGR) of high grade gliomas (HGGs) takes advantage of the accumulation of the tracer protoporphyrin IX (PpIX) in glioma cells following administration of 5-aminolevulinic acid (5-ALA). Occasionally, PpIX fluorescence intensity may be insufficient, thus compromising the efficacy and precision of the surgical intervention. The cause for the signal variation is unclear and strategies to improve the intensity of PpIX fluorescence are considered necessary. We have previously shown that differential expression of the epidermal growth factor receptor in glioblastoma cells affects PpIX fluorescence. Herein, we investigated other factors impairing PpIX accumulation and pharmacological treatments able to enhance PpIX fluorescence in glioblastoma cells displaying lower signal. In the present study we demonstrate that presence of serum in cell culture medium and differences in cellular confluence can negatively influence PpIX accumulation in U87 cell lines. We hypothesized that PpIX fluorescence intensity results from the interplay between the metabolic clearance of PpIX mediated by ferrochelatase and heme oxygenase-1 and the cellular efflux of PpIX through the ATP-binding cassette subfamily G member 2 (ABCG2). Based on the availability of compounds targeting these proteins and inhibiting them, in this study we used modulators such as genistein, an isoflavone able to inhibit ABCG2; deferoxamine, which chelate iron ions impairing FECH activity and tin protoporphyrin IX (SnPP), the specific HO-1 inhibitor. Finally, we showed the efficacy of a precisely tuned pharmacological treatment in increasing PpIX accumulation and consequently fluorescence in glioblastoma cells. This strategy may translate in more sensitive tracing of tumor cells in-vivo and improved FIGR of HGGs and possibly low grade gliomas (LGGs).
Collapse
Affiliation(s)
- Deborah Piffaretti
- Laboratory for Biomedical Neurosciences, Neurocenter of Southern Switzerland, Ente Cantonale Ospedaliero, Torricella-Taverne, Switzerland; Faculty of Medicine, Graduate School for Cellular and Biomedical Sciences, University of Bern, Bern, Switzerland
| | - Floriana Burgio
- Laboratory for Biomedical Neurosciences, Neurocenter of Southern Switzerland, Ente Cantonale Ospedaliero, Torricella-Taverne, Switzerland; Fachhochschule Nordwestschweiz (FHNW), Muttenz, Basel, Switzerland
| | - Marcus Thelen
- Institute for Research in Biomedicine (IRB), Università della Svizzera Italiana, Bellinzona, Switzerland
| | - Alain Kaelin-Lang
- Laboratory for Biomedical Neurosciences, Neurocenter of Southern Switzerland, Ente Cantonale Ospedaliero, Torricella-Taverne, Switzerland; Department of Neurology, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland; Faculty of Biomedical Neurosciences, Università della Svizzera Italiana, Lugano, Switzerland
| | - Paolo Paganetti
- Laboratory for Biomedical Neurosciences, Neurocenter of Southern Switzerland, Ente Cantonale Ospedaliero, Torricella-Taverne, Switzerland
| | - Michael Reinert
- Laboratory for Biomedical Neurosciences, Neurocenter of Southern Switzerland, Ente Cantonale Ospedaliero, Torricella-Taverne, Switzerland; Department of Neurosurgery, Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland; Department of Neurosurgery, Inselspital Bern, University of Bern, Bern, Switzerland.
| | - Maria Luisa D'Angelo
- Laboratory for Biomedical Neurosciences, Neurocenter of Southern Switzerland, Ente Cantonale Ospedaliero, Torricella-Taverne, Switzerland
| |
Collapse
|
21
|
Magalhães SC, Queiroz de Paiva JP, Kaelin-Lang A, Sterr A, Eckeli AL, Winkler AM, Fernandes do Prado G, Amaro E, Conforto AB. Short-interval intracortical inhibition is decreased in restless legs syndrome across a range of severity. Sleep Med 2019; 62:34-42. [PMID: 31539846 DOI: 10.1016/j.sleep.2019.03.021] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/11/2018] [Revised: 03/10/2019] [Accepted: 03/12/2019] [Indexed: 01/18/2023]
Abstract
BACKGROUND Decreased short-interval intracortical inhibition (SICI) to transcranial magnetic stimulation (TMS) of the primary motor cortex was described in subjects with restless legs syndrome/Willis-Ekbom disease (RLS/WED). It remained to be determined whether the magnitude of SICI decrease would be similar across levels of RLS/WED severity. Moreover, it was unknown whether, in addition to decreases in SICI, changes in cortical thickness or area could be detected in subjects with RLS/WED compared to controls. The objective of this study was to compare SICI, cortical thickness, and cortical area in subjects with idiopathic mild to moderate RLS/WED, severe to very severe RLS/WED, and controls. METHODS The severity of RLS/WED was assessed by the International Restless Legs Syndrome Severity Scale (IRLSS). SICI and 3T magnetic resonance imaging (MRI) data of subjects with RLS/WED and controls were compared. A receiver operating characteristic curve for SICI was designed for discrimination of participants with RLS/WED from controls. Cortical thickness and area were assessed by automated surface-based analysis. RESULTS SICI was significantly reduced in patients with mild to moderate and severe to very severe RLS/WED, compared to controls (one-way analysis of variance: F = 9.62, p < 0.001). Receiver operating characteristic curve analysis predicted RLS/WED when SICI was above 35% (area under the curve = 0.79, 95% CI 0.67-0.91, p < 0.001). Analyses of the whole brain and of regions of interest did not reveal differences in gray matter thickness or area between controls and subjects with RLS/WED. CONCLUSION SICI is an accurate cortical biomarker that can support the diagnosis of RLS/WED even in subjects with mild symptoms, but cortical thickness and area were not useful for discriminating subjects with this condition from controls.
Collapse
Affiliation(s)
- Samir Câmara Magalhães
- Hospital Israelita Albert Einstein, São Paulo, SP, Brazil; Universidade de Fortaleza, Unifor, Fortaleza, CE, Brazil.
| | | | | | - Annette Sterr
- Department of Psychology, University of Surrey, Guildford, Surrey, UK
| | - Alan Luiz Eckeli
- Departamento de Neurociências e Ciências do Comportamento, Divisão de Neurologia, Hospital das Clínicas da Faculdade de Medicina da USP-Ribeirão Preto, Ribeirão Preto, SP, Brazil
| | | | | | - Edson Amaro
- Hospital Israelita Albert Einstein, São Paulo, SP, Brazil; Departamento de Radiologia, Hospital das Clínicas, Universidade de São Paulo, São Paulo, SP, Brazil
| | - Adriana Bastos Conforto
- Hospital Israelita Albert Einstein, São Paulo, SP, Brazil; Departamento de Neurologia, Hospital das Clínicas, Universidade de São Paulo, São Paulo, SP, Brazil
| |
Collapse
|
22
|
Lachenmayer M, Bettschen C, Bernasconi C, Petermann K, Debove I, Muellner J, Michelis J, Burgunder J, Krauss J, Oertel M, Pollo C, Kaelin-Lang A, Schüpbach M. Stimulation of the globus pallidus internus in the treatment of Parkinson's disease: Long-term results of a monocentric cohort. Parkinsonism Relat Disord 2019; 64:118-123. [DOI: 10.1016/j.parkreldis.2019.03.009] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/26/2018] [Revised: 03/06/2019] [Accepted: 03/14/2019] [Indexed: 10/27/2022]
|
23
|
Vacchi E, Pinton S, Kaelin-Lang A, Melli G. Targeting Alpha Synuclein Aggregates in Cutaneous Peripheral Nerve Fibers by Free-floating Immunofluorescence Assay. J Vis Exp 2019. [PMID: 31305509 DOI: 10.3791/59558] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022] Open
Abstract
To date, for most neurodegenerative diseases only a post-mortem histopathological definitive diagnosis is available. For Parkinson's disease (PD), the diagnosis still relies only on clinical signs of motor involvement that appear later on in the disease course, when most of the dopaminergic neurons are already lost. Hence, there is a strong need for a biomarker that can identify patients at the beginning of disease or at the risk of developing it. Over the last few years, skin biopsy has proved to be an excellent research and diagnostic tool for peripheral nerve diseases such as small fiber neuropathy. Interestingly, a small fiber neuropathy and alpha synuclein (αSyn) neural deposits have been shown by skin biopsy in PD patients. Indeed, skin biopsy has the great advantage of being an easily accessible, minimally invasive and painless procedure that allows the analysis of peripheral nervous tissue prone to the pathology. Moreover, the possibility of repeating the skin biopsy in the course of the follow-up of the same patient allows studying the longitudinal correlation with the disease progression. We set up a standardized reliable protocol to investigate the presence of αSyn aggregates in skin nerve fibers of the PD patient. This protocol involves few short fixation steps, a cryotome sectioning and then a free-floating immunofluorescence double-staining with two specific antibodies: anti Protein Gene Product 9.5 (PGP9.5) to mark the cutaneous nerve fibers and anti 5G4 for detecting αSyn aggregates. It is a versatile, sensitive and easy to perform protocol that can also be applied for targeting other proteins of interest in skin nerves. The ability to mark αSyn aggregates is another step forward to the use of skin biopsy as a tool for establishing a pre-mortem histopathological diagnosis of PD.
Collapse
Affiliation(s)
- Elena Vacchi
- Laboratory for Biomedical Neurosciences, Neurocenter of Southern Switzerland
| | - Sandra Pinton
- Laboratory for Biomedical Neurosciences, Neurocenter of Southern Switzerland
| | - Alain Kaelin-Lang
- Laboratory for Biomedical Neurosciences, Neurocenter of Southern Switzerland; Neurology Department, Neurocenter of Southern Switzerland; Department of Neurology, Inselspital, Bern University Hospital, University of Bern; Faculty of Biomedical Sciences, Università della Svizzera Italiana
| | - Giorgia Melli
- Laboratory for Biomedical Neurosciences, Neurocenter of Southern Switzerland; Neurology Department, Neurocenter of Southern Switzerland;
| |
Collapse
|
24
|
Danieli L, Riccitelli GC, Distefano D, Prodi E, Ventura E, Cianfoni A, Kaelin-Lang A, Reinert M, Pravatà E. Brain Tumor-Enhancement Visualization and Morphometric Assessment: A Comparison of MPRAGE, SPACE, and VIBE MRI Techniques. AJNR Am J Neuroradiol 2019; 40:1140-1148. [PMID: 31221635 DOI: 10.3174/ajnr.a6096] [Citation(s) in RCA: 39] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2018] [Accepted: 05/08/2019] [Indexed: 01/08/2023]
Abstract
BACKGROUND AND PURPOSE Postgadolinium MR imaging is crucial for brain tumor diagnosis and morphometric assessment. We compared brain tumor enhancement visualization and the "target" object morphometry obtained with the most commonly used 3D MR imaging technique, MPRAGE, with 2 other routinely available techniques: sampling perfection with application-optimized contrasts by using different flip angle evolutions (SPACE) and volumetric interpolated brain examination (VIBE). MATERIALS AND METHODS Fifty-four contrast-enhancing tumors (38 gliomas and 16 metastases) were assessed using MPRAGE, VIBE, and SPACE techniques randomly acquired after gadolinium-based contrast agent administration on a 3T scanner. Enhancement conspicuity was assessed quantitatively by calculating the contrast rate and contrast-to-noise ratio, and qualitatively, by consensus visual comparative ratings. The total enhancing tumor volume and between-sequence discrepancy in the margin delineation were assessed on the corresponding 3D target objects contoured with a computer-assisted software for neuronavigation. The Wilcoxon signed rank and Pearson χ2 nonparametric tests were used to investigate between-sequence discrepancies in the contrast rate, contrast-to-noise ratio, visual conspicuity ratings, tumor volume, and margin delineation estimates. Differences were also tested for 1D (Response Evaluation Criteria in Solid Tumors) and 2D (Response Assessment in Neuro-Oncology) measurements. RESULTS Compared with MPRAGE, both SPACE and VIBE obtained higher contrast rate, contrast-to-noise ratio, and visual conspicuity ratings in both gliomas and metastases (P range, <.001-.001). The between-sequence 3D target object margin discrepancy ranged between 3% and 19.9% of lesion tumor volume. Larger tumor volumes, 1D and 2D measurements were obtained with SPACE (P range, <.01-.007). CONCLUSIONS Superior conspicuity for brain tumor enhancement can be achieved using SPACE and VIBE techniques, compared with MPRAGE. Discrepancies were also detected when assessing target object size and morphology, with SPACE providing more accurate estimates.
Collapse
Affiliation(s)
- L Danieli
- From the Departments of Neuroradiology (L.D., D.D., E.P., E.V., A.C., E.P.)
| | - G C Riccitelli
- Neurology (G.C.R., A.K.-L.).,Neuroimaging Research Unit (G.C.R.), Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy
| | - D Distefano
- From the Departments of Neuroradiology (L.D., D.D., E.P., E.V., A.C., E.P.)
| | - E Prodi
- From the Departments of Neuroradiology (L.D., D.D., E.P., E.V., A.C., E.P.)
| | - E Ventura
- From the Departments of Neuroradiology (L.D., D.D., E.P., E.V., A.C., E.P.)
| | - A Cianfoni
- From the Departments of Neuroradiology (L.D., D.D., E.P., E.V., A.C., E.P.).,Departments of Neuroradiology (A.C.)
| | - A Kaelin-Lang
- Neurology (G.C.R., A.K.-L.).,Neurology (A.K.-L.), Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.,Faculty of Biomedical Sciences (A.K.-L., M.R.), Università della Svizzera Italiana, Lugano, Switzerland
| | - M Reinert
- Neurosurgery (M.R.), Neurocenter of Southern Switzerland, Lugano, Switzerland.,Faculty of Biomedical Sciences (A.K.-L., M.R.), Università della Svizzera Italiana, Lugano, Switzerland
| | - E Pravatà
- From the Departments of Neuroradiology (L.D., D.D., E.P., E.V., A.C., E.P.)
| |
Collapse
|
25
|
Amato N, Manconi M, Möller JC, Sarasso S, Stanzione P, Staedler C, Kaelin-Lang A, Galati S. Levodopa-induced dyskinesia in Parkinson disease: Sleep matters. Ann Neurol 2018; 84:905-917. [DOI: 10.1002/ana.25360] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2018] [Revised: 10/09/2018] [Accepted: 10/10/2018] [Indexed: 12/11/2022]
Affiliation(s)
- Ninfa Amato
- Sleep and Epilepsy Center, Neurocenter of Southern Switzerland; Lugano Switzerland
| | - Mauro Manconi
- Sleep and Epilepsy Center, Neurocenter of Southern Switzerland; Lugano Switzerland
| | - Jens C. Möller
- Parkinson Center; Zihlschlacht-Sitterdorf Switzerland
- Department of Neurology; Philipp University of Marburg; Marburg Germany
| | - Simone Sarasso
- L. Sacco Department of Biomedical and Clinical Sciences; University of Milan; Milan Italy
| | - Paolo Stanzione
- Department of Medical Systems; University of Rome Tor Vergata; Rome Italy
| | - Claudio Staedler
- Sleep and Epilepsy Center, Neurocenter of Southern Switzerland; Lugano Switzerland
| | - Alain Kaelin-Lang
- Sleep and Epilepsy Center, Neurocenter of Southern Switzerland; Lugano Switzerland
- University of Italian Switzerland; Lugano Switzerland
| | - Salvatore Galati
- Sleep and Epilepsy Center, Neurocenter of Southern Switzerland; Lugano Switzerland
- University of Italian Switzerland; Lugano Switzerland
| |
Collapse
|
26
|
Melli G, Vacchi E, Biemmi V, Galati S, Staedler C, Ambrosini R, Kaelin-Lang A. Cervical skin denervation associates with alpha-synuclein aggregates in Parkinson disease. Ann Clin Transl Neurol 2018; 5:1394-1407. [PMID: 30480033 PMCID: PMC6243385 DOI: 10.1002/acn3.669] [Citation(s) in RCA: 39] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2018] [Revised: 09/17/2018] [Accepted: 09/19/2018] [Indexed: 01/22/2023] Open
Abstract
Objective Autonomic nervous system is involved at the onset of Parkinson disease (PD), and alpha‐synuclein (α‐Syn) and its phosphorylated form (p‐αSyn) have been detected in dermal autonomic nerve fibers of PD. We assessed disease specific conformation variant of α‐Syn immunoreactivity in cutaneous nerves and characterized skin denervation patterns in PD and atypical parkinsonism (AP). Methods We enrolled 49 subjects, 19 with PD, 17 age‐matched healthy controls, and 13 with AP. The manifestations of disease were rated on clinical scales. Skin biopsies from ankle, thigh, and neck were analyzed by immunofluorescence for p‐αSyn, 5G4 as a conformation specific antibody to pathogenic α‐Syn and PGP9.5 as axonal marker. Intraepidermal nerve fiber density was measured in all anatomical sites as marker of neurodegeneration. Thirteen of the 19 PD underwent a 1 year follow‐up visit plus skin biopsies. Results PD subjects displayed more severe cervical skin denervation (P < 0.03), which correlated to disease duration and worsened between initial and follow‐up examination (P < 0.001). p‐αSyn and 5G4 were equally sensitive and specific for the diagnosis of PD (area under the ROC was 0.839 for p‐αSyn and 0.886 for 5G4). PD and AP with possible alpha‐synucleinopathies share the features of marked cervical denervation and the presence of 5G4. In contrast AP with possible tauopathies were normal. Interpretation Conformational specific forms of α‐Syn are detectable in skin biopsy by immunofluorescence in PD, with a promising diagnostic efficiency similar to p‐αSyn. Cervical cutaneous denervation correlates with disease duration and increases over time standing out as a potential biomarker of PD progression.
Collapse
Affiliation(s)
- Giorgia Melli
- Laboratory for Biomedical Neurosciences Neurocentre of Southern Switzerland Via ai Söi 24. CH-6807 Torricella-Taverne Switzerland.,Neurology Department Neurocentre of Southern Switzerland Via Tesserete 46 CH-6900 Lugano Switzerland
| | - Elena Vacchi
- Laboratory for Biomedical Neurosciences Neurocentre of Southern Switzerland Via ai Söi 24. CH-6807 Torricella-Taverne Switzerland
| | - Vanessa Biemmi
- Laboratory for Biomedical Neurosciences Neurocentre of Southern Switzerland Via ai Söi 24. CH-6807 Torricella-Taverne Switzerland
| | - Salvatore Galati
- Laboratory for Biomedical Neurosciences Neurocentre of Southern Switzerland Via ai Söi 24. CH-6807 Torricella-Taverne Switzerland.,Neurology Department Neurocentre of Southern Switzerland Via Tesserete 46 CH-6900 Lugano Switzerland
| | - Claudio Staedler
- Neurology Department Neurocentre of Southern Switzerland Via Tesserete 46 CH-6900 Lugano Switzerland
| | - Roberto Ambrosini
- Department of Environmental Science and Policy University of Milan Via Celoria 26, I-20133 Milan Italy
| | - Alain Kaelin-Lang
- Laboratory for Biomedical Neurosciences Neurocentre of Southern Switzerland Via ai Söi 24. CH-6807 Torricella-Taverne Switzerland.,Neurology Department Neurocentre of Southern Switzerland Via Tesserete 46 CH-6900 Lugano Switzerland.,Department of Neurology Inselspital Bern University Hospital University of Bern Freiburgstrasse 4,3010 Bern Switzerland
| |
Collapse
|
27
|
Grandi LC, Kaelin-Lang A, Orban G, Song W, Salvadè A, Stefani A, Di Giovanni G, Galati S. Oscillatory Activity in the Cortex, Motor Thalamus and Nucleus Reticularis Thalami in Acute TTX and Chronic 6-OHDA Dopamine-Depleted Animals. Front Neurol 2018; 9:663. [PMID: 30210425 PMCID: PMC6122290 DOI: 10.3389/fneur.2018.00663] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2018] [Accepted: 07/24/2018] [Indexed: 01/08/2023] Open
Abstract
The motor thalamus (MTh) and the nucleus reticularis thalami (NRT) have been largely neglected in Parkinson's disease (PD) research, despite their key role as interface between basal ganglia (BG) and cortex (Cx). In the present study, we investigated the oscillatory activity within the Cx, MTh, and NRT, in normal and different dopamine (DA)-deficient states. We performed our experiments in both acute and chronic DA-denervated rats by injecting into the medial forebrain bundle (MFB) tetrodotoxin (TTX) or 6-hydroxydopamine (6-OHDA), respectively. Interestingly, almost all the electroencephalogram (EEG) frequency bands changed in acute and/or chronic DA depletion, suggesting alteration of all oscillatory activities and not of a specific band. Overall, δ (2-4 Hz) and θ (4-8 Hz) band decreased in NRT and Cx in acute and chronic state, whilst, α (8-13 Hz) band decreased in acute and chronic states in the MTh and NRT but not in the Cx. The β (13-40 Hz) and γ (60-90 Hz) bands were enhanced in the Cx. In the NRT the β bands decreased, except for high-β (Hβ, 25-30 Hz) that increased in acute state. In the MTh, Lβ and Hβ decreased in acute DA depletion state and γ decreased in both TTX and 6-OHDA-treated animals. These results confirm that abnormal cortical β band are present in the established DA deficiency and it might be considered a hallmark of PD. The abnormal oscillatory activity in frequency interval of other bands, in particular the dampening of low frequencies in thalamic stations, in both states of DA depletion might also underlie PD motor and non-motor symptoms. Our data highlighted the effects of acute depletion of DA and the strict interplay in the oscillatory activity between the MTh and NRT in both acute and chronic stage of DA depletion. Moreover, our findings emphasize early alterations in the NRT, a crucial station for thalamic information processing.
Collapse
Affiliation(s)
- Laura C. Grandi
- Laboratory for Biomedical Neurosciences, Neurocenter of Southern Switzerland, Taverne, Switzerland
| | - Alain Kaelin-Lang
- Laboratory for Biomedical Neurosciences, Neurocenter of Southern Switzerland, Taverne, Switzerland
- Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
- Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland
| | - Gergely Orban
- Laboratory for Biomedical Neurosciences, Neurocenter of Southern Switzerland, Taverne, Switzerland
| | - Wei Song
- Laboratory for Biomedical Neurosciences, Neurocenter of Southern Switzerland, Taverne, Switzerland
| | - Agnese Salvadè
- Laboratory for Biomedical Neurosciences, Neurocenter of Southern Switzerland, Taverne, Switzerland
| | - Alessandro Stefani
- Department System Medicine, UOSD Parkinson, University of Rome Tor Vergata, Rome, Italy
| | - Giuseppe Di Giovanni
- Department of Physiology and Biochemistry, Faculty of Medicine and Surgery, University of Malta, Msida, Malta
- Neuroscience Division, School of Biosciences, Cardiff University, Cardiff, United Kingdom
| | - Salvatore Galati
- Laboratory for Biomedical Neurosciences, Neurocenter of Southern Switzerland, Taverne, Switzerland
| |
Collapse
|
28
|
Caverzasio S, Amato N, Manconi M, Prosperetti C, Kaelin-Lang A, Hutchison WD, Galati S. Brain plasticity and sleep: Implication for movement disorders. Neurosci Biobehav Rev 2018; 86:21-35. [DOI: 10.1016/j.neubiorev.2017.12.009] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2017] [Revised: 12/15/2017] [Accepted: 12/18/2017] [Indexed: 12/31/2022]
|
29
|
Ratti P, Faraci F, Hackethal S, Pereno M, Ferlito C, Mascheroni A, Caverzasio S, Bonoli S, Guglielmetti L, Amato N, Puiatti A, Kaelin-Lang A. Bedtime to morning variation of mobility after nocturnal sleep in Parkinson's disease. Sleep Med 2017. [DOI: 10.1016/j.sleep.2017.11.809] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
30
|
Fiechter M, Nowacki A, Oertel MF, Fichtner J, Debove I, Lachenmayer ML, Wiest R, Bassetti CL, Raabe A, Kaelin-Lang A, Schüpbach MW, Pollo C. Deep Brain Stimulation for Tremor: Is There a Common Structure? Stereotact Funct Neurosurg 2017; 95:243-250. [DOI: 10.1159/000478270] [Citation(s) in RCA: 37] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2016] [Accepted: 06/08/2017] [Indexed: 12/19/2022]
|
31
|
de Paiva JPQ, Magalhães SC, do Prado GF, Eckeli AL, Kaelin-Lang A, Conforto AB. The duration of the cortical silent period is not abnormal in Restless Legs Syndrome/Willis-Ekbom Disease. J Neurol Sci 2017; 375:35-42. [PMID: 28320166 DOI: 10.1016/j.jns.2016.12.066] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2016] [Revised: 11/28/2016] [Accepted: 12/28/2016] [Indexed: 12/14/2022]
Abstract
OBJECTIVE To compare the duration of the cortical silent period (CSP) measured in a hand muscle in subjects with primary Restless Legs Syndrome (RLS/WED) and controls, using four different methods of analysis. METHODS The CSP to transcranial magnetic stimulation of the dominant motor cortex was assessed in the abductor digiti minimi of 33 subjects with RLS/WED and 24 controls. CSP duration was measured by an automated and three visually-guided methods. RESULTS There were significant differences between absolute values of CSP duration according to the method of analysis. However, irrespectively of the method used for CSP assessment, no differences were found between measurements performed in subjects with RLS/WED and subjects from the control group. CONCLUSIONS Absolute values of CSP durations analyzed by different methods should not be directly compared, because significantly different results can be obtained from the same data set. SIGNIFICANCE The CSP assessed from a hand muscle is unlikely to be a biomarker of primary RLS/WED. Our results highlight the importance of standardizing the definition of CSP onset and offset, as well as of describing in detail the methodology chosen to record and measure CSP duration, in order to enable comparisons between studies.
Collapse
Affiliation(s)
- Joselisa Péres Queiroz de Paiva
- Hospital Israelita Albert Einstein, Edifício Josef Féher (Bloco A), 2° subsolo, Av. Albert Einstein, 627/701, São Paulo, SP, Brazil CEP: 05652-900.
| | - Samir Câmara Magalhães
- Hospital Israelita Albert Einstein, Edifício Josef Féher (Bloco A), 2° subsolo, Av. Albert Einstein, 627/701, São Paulo, SP, Brazil CEP: 05652-900.
| | - Gilmar Fernandes do Prado
- Universidade Federal de São Paulo, Departamento de Neurologia e Neurocirurgia, Rua Claúdio Rossi, 394, São Paulo, SP, Brazil CEP: 01547-000.
| | - Alan Luiz Eckeli
- Hospital das Clínicas da Faculdade de Medicina, Departamento de Neurociências e Ciências do Comportamento, Divisão de Neurologia, Hospital das Clinicas de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil CEP: 14.048-900.
| | - Alain Kaelin-Lang
- Neurocenter of Southern Switzerland, LBN - Laboratory for Biomedical Neurosciences, 6900 Lugano, Switzerland.
| | - Adriana Bastos Conforto
- Hospital Israelita Albert Einstein, Edifício Josef Féher (Bloco A), 2° subsolo, Av. Albert Einstein, 627/701, São Paulo, SP, Brazil CEP: 05652-900; Hospital das Clínicas da Faculdade de Medicina, Departamento de Neurologia e Núcleo de Apoio à Pesquisa em Neurociência Aplicada (NAPNA), Universidade de São Paulo, São Paulo, SP, Brazil CEP: 05403-010.
| |
Collapse
|
32
|
Maino P, Koetsier E, Kaelin-Lang A, Gobbi C, Perez R. Efficacious Dorsal Root Ganglion Stimulation for Painful Small Fiber Neuropathy: A Case Report. Pain Physician 2017; 20:E459-E463. [PMID: 28339448] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Small fiber neuropathy is a disorder of the peripheral nerves with typical symptoms of burning, sharp, and shooting pain and sensory disturbances in the feet. Pain treatment depends principally on the underlying etiology with concurrent administration of antidepressants, anticonvulsants, opioids, and topical treatments like capsaicin and local anesthetics. However, treatments for pain relief in these patients frequently fail. We describe the first case of intractable painful small fiber neuropathy of the foot successfully treated with spinal cord stimulation of the left L5 dorsal root ganglion.A 74-year-old man presented at our clinic with severe intractable pain, dysesthesia, and allodynia of the left foot caused by idiopathic small fiber neuropathy, confirmed by skin biopsy. His pain score was 8 on a standard 0 - 10 numeric rating scale. As the pain was not satisfactorily controlled by conventional therapy, dorsal root ganglion stimulation was proposed to the patient and, after informed consent, a specifically designed percutaneous stimulation lead was placed over the left L5 dorsal root ganglion and connected to an external neurostimulator. After a positive trial of 10 days, a permanent neurostimulator was implanted. Twenty months post-implantation the patient continued to experience stimulation-induced paresthesia covering the entire pain area and reported a pain rating of 4.Results from the case report demonstrate that the dorsal root ganglion is a promising neural stimulation target to treat neuropathic pain due to intractable small fiber neuropathy. Prospective controlled studies are warranted to confirm the efficacy of this treatment as an option for the aforementioned condition.Key words: Dorsal root ganglion stimulation, small fiber neuropathy, neuropathic pain.
Collapse
Affiliation(s)
- Paolo Maino
- Ospedale Regionale di Lugano, Viganello, Switzerland
| | - Eva Koetsier
- Ospedale Regionale di Lugano, Viganello, Switzerland
| | | | - Claudio Gobbi
- Ospedale Regionale di Lugano, Viganello, Switzerland
| | - Roberto Perez
- Department of Anesthesiology, VU University Medical Center, Amsterdam; Trauma Related Neuronal Dysfunction (TREND), Delft; EMGO+ Institute for Health and Care Research, Amsterdam
| |
Collapse
|
33
|
Oertel MF, Schüpbach WMM, Ghika JA, Stieglitz LH, Fiechter M, Kaelin-Lang A, Raabe A, Pollo C. Combined thalamic and subthalamic deep brain stimulation for tremor-dominant Parkinson's disease. Acta Neurochir (Wien) 2017; 159:265-269. [PMID: 27966027 DOI: 10.1007/s00701-016-3044-5] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2016] [Accepted: 11/28/2016] [Indexed: 12/30/2022]
Abstract
Deep brain stimulation (DBS) in the thalamic ventral intermediate (Vim) or the subthalamic nucleus (STN) reportedly improves medication-refractory Parkinson's disease (PD) tremor. However, little is known about the potential synergic effects of combined Vim and STN DBS. We describe a 79-year-old man with medication-refractory tremor-dominant PD. Bilateral Vim DBS electrode implantation produced insufficient improvement. Therefore, the patient underwent additional unilateral left-sided STN DBS. Whereas Vim or STN stimulation alone led to partial improvement, persisting tremor resolution occurred after simultaneous stimulation. The combination of both targets may have a synergic effect and is an alternative option in suitable cases.
Collapse
Affiliation(s)
- Markus F Oertel
- Department of Neurosurgery, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 10, 3010, Bern, Switzerland.
| | - W Michael M Schüpbach
- Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
| | | | - Lennart H Stieglitz
- Department of Neurosurgery, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 10, 3010, Bern, Switzerland
- Department of Neurosurgery, Zurich University Hospital, University of Zurich, Zurich, Switzerland
| | - Michael Fiechter
- Department of Neurosurgery, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 10, 3010, Bern, Switzerland
| | - Alain Kaelin-Lang
- Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
- Neurocenter of Southern Switzerland, Lugano, Switzerland
| | - Andreas Raabe
- Department of Neurosurgery, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 10, 3010, Bern, Switzerland
| | - Claudio Pollo
- Department of Neurosurgery, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 10, 3010, Bern, Switzerland
| |
Collapse
|
34
|
Grunt S, Newman CJ, Saxer S, Steinlin M, Weisstanner C, Kaelin-Lang A. The Mirror Illusion Increases Motor Cortex Excitability in Children With and Without Hemiparesis. Neurorehabil Neural Repair 2016; 31:280-289. [PMID: 27909072 DOI: 10.1177/1545968316680483] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
BACKGROUND Mirror therapy provides a visual illusion of a normal moving limb by using the mirror reflection of the unaffected arm instead of viewing the paretic limb and is used in rehabilitation to improve hand function. Little is known about the mechanism underlying its effect in children with hemiparesis. OBJECTIVE To investigate the effect of the mirror illusion (MI) on the excitability of the primary motor cortex (M1) in children and adolescents. METHODS Twelve patients with hemiparesis (10-20 years) and 8 typically developing subjects (8-17 years) participated. Corticospinal reorganization was classified as contralateral (projection from contralateral hemisphere to affected hand) or ipsilateral (projection from ipsilateral hemisphere to affected hand). M1 excitability of the hemisphere projecting to the affected (nondominant in typically developing subjects) hand was obtained during 2 different conditions using single-pulse transcranial magnetic stimulation (TMS). Each condition (without/with mirror) consisted of a unimanual and a bimanual task. Motor-evoked potentials (MEPs) were recorded from the abductor pollicis brevis and flexor digitorum superficialis muscles. RESULTS MEP amplitudes were significantly increased during the mirror condition ( P = .005) in typically developing subjects and in patients with contralateral reorganization. No significant effect of MI was found in subjects with ipsilateral reorganization. MI increased M1 excitability during active movements only. This increase was not correlated to hand function. CONCLUSION MI increases the excitability of M1 in hemiparetic patients with contralateral corticospinal organization and in typically developing subjects. This finding provides neurophysiological evidence supporting the application of mirror therapy in selected children and adolescents with hemiparesis.
Collapse
Affiliation(s)
- Sebastian Grunt
- 1 Division of Neuropaediatrics, Development and Rehabilitation, University Children's Hospital Bern, Inselspital, Bern University Hospital, University of Bern, Switzerland
| | - Christopher J Newman
- 2 Paediatric Neurology and Neurorehabilitation Unit, Lausanne University Hospital, Lausanne, Switzerland
| | - Stefanie Saxer
- 1 Division of Neuropaediatrics, Development and Rehabilitation, University Children's Hospital Bern, Inselspital, Bern University Hospital, University of Bern, Switzerland.,3 Institute of Human Movement Sciences and Sport, ETH Zürich, Switzerland
| | - Maja Steinlin
- 1 Division of Neuropaediatrics, Development and Rehabilitation, University Children's Hospital Bern, Inselspital, Bern University Hospital, University of Bern, Switzerland
| | - Christian Weisstanner
- 4 University Institute of Diagnostic and Interventional Neuroradiology, University Hospital, Bern, Switzerland
| | - Alain Kaelin-Lang
- 5 University Clinic of Neurology, University Hospital, Bern, Switzerland.,6 Neurocenter of Southern Switzerland, Ospedale Civico, Lugano, Switzerland
| |
Collapse
|
35
|
Salvadè A, D'Angelo V, Di Giovanni G, Tinkhauser G, Sancesario G, Städler C, Möller JC, Stefani A, Kaelin-Lang A, Galati S. Distinct roles of cortical and pallidal β and γ frequencies in hemiparkinsonian and dyskinetic rats. Exp Neurol 2016; 275 Pt 1:199-208. [DOI: 10.1016/j.expneurol.2015.11.005] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2015] [Revised: 09/21/2015] [Accepted: 11/10/2015] [Indexed: 01/25/2023]
|
36
|
Trendafilov V, Sarasso S, Moeller J, Staedler C, Kaelin-Lang A, Galati S. Synaptic homeostasis in Parkinson's disease: An high-density EEG study in different stage of the disease. Parkinsonism Relat Disord 2016. [DOI: 10.1016/j.parkreldis.2015.10.389] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
37
|
Orban G, Song W, Kaelin-Lang A, Galati S. Integration of cortical and basal ganglia inputs in motor thalamus of parkinsonian animal models. Parkinsonism Relat Disord 2016. [DOI: 10.1016/j.parkreldis.2015.10.611] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
38
|
Orban G, Song W, Kaelin-Lang A, Galati S. Integration of cortical and basal ganglia inputs in motor thalamus of parkinsonian animal models. Parkinsonism Relat Disord 2016. [DOI: 10.1016/j.parkreldis.2015.10.451] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
39
|
Muellner J, Kaelin-Lang A, Pfeiffer O, El-Koussy MM. Neurogenic thoracic outlet syndrome due to subclavius posticus muscle with dynamic brachial plexus compression: a case report. BMC Res Notes 2015; 8:351. [PMID: 26268814 PMCID: PMC4535788 DOI: 10.1186/s13104-015-1317-3] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2014] [Accepted: 08/04/2015] [Indexed: 11/17/2022] Open
Abstract
Background Neurogenic thoracic outlet syndrome is an underestimated cause of brachial weakness and pain. The subclavius posticus muscle (SPM) is an aberrant muscle originating from the medial aspect of the first rib reaching to superior border of the scapula, which may cause, depending on its activation, dynamic compression of the brachial plexus. Case presentation In the present study, we report about a 32-year-old male caucasian patient with weakness in radial deviation of his left hand. An isolated macrodactyly of his left middle finger had been operated twice. Electroneurography showed a carpal-tunnel-syndrome (CTS) on the left side. MRI of the brachial plexus revealed an additional muscle in the costoclavicular space, identified as SPM. To our knowledge, this is the second case report of a neurogenic thoracic outlet syndrome due to SPM, and the first case described with isolated macrodactyly and CTS in the same patient. Conclusion If complaints about hand weakness are only reported in cases of distinct hand positions, a dynamic compression of the brachial plexus by SPM may be the cause. A neurogenic thoracic outlet syndrome may facilitate the development of CTS.
Collapse
Affiliation(s)
- Julia Muellner
- Department of Neurology, University Hospital Bern, Freiburgstrasse 100, 3010, Bern, Switzerland.
| | - Alain Kaelin-Lang
- Neurocenter of Southern Switzerland, Opsedale Civico, Via Tesserete 46, 6900, Lugano, Switzerland.
| | - Oliver Pfeiffer
- Department of Neuroradiology, University Hospital Bern, Bern, Switzerland.
| | | |
Collapse
|
40
|
Kornfeld S, Delgado Rodríguez JA, Everts R, Kaelin-Lang A, Wiest R, Weisstanner C, Mordasini P, Steinlin M, Grunt S. Cortical reorganisation of cerebral networks after childhood stroke: impact on outcome. BMC Neurol 2015; 15:90. [PMID: 26058895 PMCID: PMC4466862 DOI: 10.1186/s12883-015-0309-1] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2014] [Accepted: 03/17/2015] [Indexed: 12/23/2022] Open
Abstract
BACKGROUND Recovery after arterial ischaemic stroke is known to largely depend on the plastic properties of the brain. The present study examines changes in the network topography of the developing brain after stroke. Effects of brain damage are best assessed by examining entire networks rather than single sites of structural lesions. Relating these changes to post-stroke neuropsychological variables and motor abilities will improve understanding of functional plasticity after stroke. Inclusion of healthy controls will provide additional insight into children's normal brain development. Resting state functional magnetic resonance imaging is a valid approach to topographically investigate the reorganisation of functional networks after a brain lesion. Transcranial magnetic stimulation provides complementary output information. This study will investigate functional reorganisation after paediatric arterial ischaemic stroke by means of resting state functional magnetic resonance imaging and transcranial magnetic stimulation in a cross-sectional plus longitudinal study design. The general aim of this study is to better understand neuroplasticity of the developing brain after stroke in order to develop more efficacious therapy and to improve the post-stroke functional outcome. METHODS The cross-sectional part of the study will investigate the functional cerebral networks of 35 children with chronic arterial ischaemic stroke (time of the lesion >2 years). In the longitudinal part, 15 children with acute arterial ischaemic stroke (shortly after the acute phase of the stroke) will be included and investigations will be performed 3 times within the subsequent 9 months. We will also recruit 50 healthy controls, matched for age and sex. The neuroimaging and neurophysiological data will be correlated with neuropsychological and neurological variables. DISCUSSION This study is the first to combine resting state functional magnetic resonance imaging and transcranial magnetic stimulation in a paediatric population diagnosed with arterial ischaemic stroke. Thus, this study has the potential to uniquely contribute to the understanding of neuronal plasticity in the brains of healthy children and those with acute or chronic brain injury. It is expected that the results will lead to the development of optimal interventions after arterial ischaemic stroke.
Collapse
Affiliation(s)
- Salome Kornfeld
- Division of Neuropaediatrics, Development and Rehabilitation, Children's University Hospital, Inselspital, Bern, Switzerland. .,Center for Cognition, Learning and Memory, University of Bern, Bern, Switzerland.
| | - Juan Antonio Delgado Rodríguez
- Division of Neuropaediatrics, Development and Rehabilitation, Children's University Hospital, Inselspital, Bern, Switzerland. .,Graduate School for Health Sciences, University of Bern, Bern, Switzerland.
| | - Regula Everts
- Division of Neuropaediatrics, Development and Rehabilitation, Children's University Hospital, Inselspital, Bern, Switzerland. .,Center for Cognition, Learning and Memory, University of Bern, Bern, Switzerland.
| | | | - Roland Wiest
- Department of Diagnostic and Interventional Neuroradiology, University Hospital, Inselspital, Bern, Switzerland.
| | - Christian Weisstanner
- Department of Diagnostic and Interventional Neuroradiology, University Hospital, Inselspital, Bern, Switzerland.
| | - Pasquale Mordasini
- Department of Diagnostic and Interventional Neuroradiology, University Hospital, Inselspital, Bern, Switzerland.
| | - Maja Steinlin
- Division of Neuropaediatrics, Development and Rehabilitation, Children's University Hospital, Inselspital, Bern, Switzerland. .,Center for Cognition, Learning and Memory, University of Bern, Bern, Switzerland.
| | - Sebastian Grunt
- Division of Neuropaediatrics, Development and Rehabilitation, Children's University Hospital, Inselspital, Bern, Switzerland.
| |
Collapse
|
41
|
Magalhães SC, Kaelin-Lang A, Sterr A, do Prado GF, Eckeli AL, Conforto AB. Transcranial magnetic stimulation for evaluation of motor cortical excitability in restless legs syndrome/Willis-Ekbom disease. Sleep Med 2015; 16:1265-73. [PMID: 26429756 DOI: 10.1016/j.sleep.2015.03.018] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/20/2014] [Revised: 02/27/2015] [Accepted: 03/29/2015] [Indexed: 11/30/2022]
Abstract
There is no consensus about mechanisms underlying restless legs syndrome (RLS), also known as Willis-Ekbom disease (WED). Cortical excitability may be abnormal in RLS. Transcranial magnetic stimulation (TMS) can provide insight about cortical excitability. We reviewed studies about measures of excitability to TMS in RLS. Original studies published between January 1999 and January 2015 were searched in PubMed, Scopus, and Web of Science databases. Inclusion criteria were as follows: original studies involving primary RLS in patients from both sexes and ages between 18 and 85 years; TMS protocols clearly described; and they were written in English, in peer-reviewed journals. Fifteen manuscripts were identified. TMS protocols were heterogeneous across studies. Resting motor threshold, active motor threshold, and amplitudes of motor-evoked potentials were typically reported to be normal in RLS. A reduction in short-interval intracortical inhibition (SICI) was the most consistent finding, whereas conflicting results were described in regard to short-interval intracortical facilitation and the contralateral silent period. Decreased SICI can be reversed by treatment with dopaminergic agonists. Plasticity in the motor cortex and sensorimotor integration may be disrupted. TMS may become a useful biomarker of responsiveness to drug treatment in RLS. The field can benefit from increases in homogeneity and sizes of samples, as well as from decrease in methodological variability across studies.
Collapse
Affiliation(s)
| | | | | | | | - Alan Luiz Eckeli
- Hospital das Clínicas da Faculdade de Medicina da USP, Ribeirão Preto, São Paulo, Brazil
| | | |
Collapse
|
42
|
Galati S, Salvadè A, Pace M, Sarasso S, Baracchi F, Bassetti CL, Kaelin-Lang A, Städler C, Stanzione P, Möller JC. Evidence of an association between sleep and levodopa-induced dyskinesia in an animal model of Parkinson's disease. Neurobiol Aging 2015; 36:1577-89. [DOI: 10.1016/j.neurobiolaging.2014.12.018] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2014] [Revised: 11/01/2014] [Accepted: 12/15/2014] [Indexed: 01/15/2023]
|
43
|
Sgroi S, Kaelin-Lang A, Capper-Loup C. Spontaneous locomotor activity and L-DOPA-induced dyskinesia are not linked in 6-OHDA parkinsonian rats. Front Behav Neurosci 2014; 8:331. [PMID: 25324746 PMCID: PMC4183109 DOI: 10.3389/fnbeh.2014.00331] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2014] [Accepted: 09/04/2014] [Indexed: 12/26/2022] Open
Abstract
Bradykinesia (slowness of movement) and other characteristic motor manifestations of Parkinson's disease (PD) are alleviated by treatment with L-dihydroxyphenylalanine (L-DOPA). Long-term L-DOPA treatment, however, is associated with complications such as motor fluctuations and dyskinesia that severely impair the quality of life. It is unclear whether the effect of L-DOPA on spontaneous motor activity and its dyskinesia-inducing effect share a common mechanism. To investigate the possible connection between these two effects, we analyzed the spontaneous locomotor activity of parkinsonian rats before surgery (unilateral injection of 6-OHDA in the right medial forebrain bundle), before treatment with L-DOPA, during L-DOPA treatment (the "ON" phase), and after the end of L-DOPA treatment (the "OFF" phase). We correlated the severity of dyskinesia (AIM scores) with locomotor responses in the ON/OFF phases of chronic L-DOPA treatment at two different doses. We treated three groups of parkinsonian animals with chronic injections of 8 mg/kg L-DOPA, 6 mg/kg L-DOPA, and saline solution and one group of non-lesioned animals with 8 mg/kg L-DOPA. At the end of the experiment, tyrosine hydroxylase (TH) immunoreactivity was analyzed in the striatum of all parkinsonian rats. We found no correlation between the severity of dyskinesia and spontaneous locomotor activity in the ON or OFF phase of L-DOPA treatment. The only observed correlation was between the pathological rotation induced by L-DOPA at the highest dose and locomotor activity in the ON phase of L-DOPA treatment. In addition, a L-DOPA withdrawal effect was observed, with worse motor performance in the OFF phase than before the start of L-DOPA treatment. These findings suggest that different neural mechanisms underlie the effect of L-DOPA on spontaneous motor activity and its dyskinesia-inducing effect, with a different dose-response relationship for each of these two effects.
Collapse
Affiliation(s)
- Stefania Sgroi
- Department of Neurology and Department of Clinical Research, Movement Disorders Center, Inselspital, Bern University Hospital, and University of BernBern, Switzerland
- Graduate School for Cellular and Biomedical Sciences, University of BernBern, Switzerland
- Neurocentre of Southern SwitzerlandLugano, Switzerland
| | - Alain Kaelin-Lang
- Department of Neurology and Department of Clinical Research, Movement Disorders Center, Inselspital, Bern University Hospital, and University of BernBern, Switzerland
- Neurocentre of Southern SwitzerlandLugano, Switzerland
| | - Christine Capper-Loup
- Department of Neurology and Department of Clinical Research, Movement Disorders Center, Inselspital, Bern University Hospital, and University of BernBern, Switzerland
| |
Collapse
|
44
|
Capper-Loup C, Kaelin-Lang A. Locomotor velocity and striatal adaptive gene expression changes of the direct and indirect pathways in Parkinsonian rats. J Parkinsons Dis 2014; 3:341-9. [PMID: 23948996 DOI: 10.3233/jpd-130202] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
BACKGROUND In Parkinson's disease (PD), bradykinesia, or slowness of movement, only appears after a large striatal dopamine depletion. Compensatory mechanisms probably play a role in this delayed appearance of symptoms. OBJECTIVE Our hypothesis is that the striatal direct and indirect pathways participate in these compensatory mechanisms. METHODS We used the unilateral 6-hydroxydopamine (6-OHDA) rat model of PD and control animals. Four weeks after the lesion, the spontaneous locomotor activity of the rats was measured and then the animals were killed and their brain extracted. We quantified the mRNA expression of markers of the striatal direct and indirect pathways as well as the nigral expression of dopamine transporter (DAT) and tyrosine hydroxylase (TH) mRNA. We also carried out an immunohistochemistry for the striatal TH protein expression. RESULTS As expected, the unilateral 6-OHDA rats presented a tendency to an ipsilateral head turning and a low locomotor velocity. In 6-OHDA rats only, we observed a significant and positive correlation between locomotor velocity and both D1-class dopamine receptor (D1R) (direct pathway) and enkephalin (ENK) (indirect pathway) mRNA in the lesioned striatum, as well as between D1R and ENK mRNA. CONCLUSIONS Our results demonstrate a strong relationship between both direct and indirect pathways and spontaneous locomotor activity in the parkinsonian rat model. We suggest a synergy between both pathways which could play a role in compensatory mechanisms and may contribute to the delayed appearance of bradykinesia in PD.
Collapse
Affiliation(s)
- Christine Capper-Loup
- Movement Disorders Center, Department of Neurology and Department of Clinical Research, Inselspital, Bern University Hospital and University of Bern, Switzerland
| | | |
Collapse
|
45
|
Brugger F, Schüpbach M, Koenig M, Müri R, Bohlhalter S, Kaelin-Lang A, Kamm CP, Kägi G. The Clinical Spectrum of Ataxia with Oculomotor Apraxia Type 2. Mov Disord Clin Pract 2014; 1:106-109. [PMID: 30363866 DOI: 10.1002/mdc3.12021] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2013] [Revised: 03/10/2014] [Accepted: 03/12/2014] [Indexed: 11/07/2022] Open
Abstract
Ataxia with oculomotor apraxia type 2 (AOA2) is an inherited disorder caused by mutations within both alleles of the senataxin gene. First symptoms are usually recognized before the age of 30. Unlike several other autosomal recessive cerebellar ataxia syndromes, levels of alpha-fetoprotein are nearly always elevated in AOA2 and thus narrowing down the differential diagnosis list. We present 3 video cases illustrating and expanding the clinical spectrum of AOA2, with 1 case bearing a novel mutation with cervical dystonia as the first symptom, the absence of neuropathy, and a disease onset beyond the age of 40. Furthermore, all patients were assessed by oculographic analysis, which revealed distinct patterns of oculomotor abnormalities. The clinical spectrum of AOA2 might be even broader than previously described in larger series. Oculography might be a useful tool to detect subclinical oculomotor apraxia in this disorder.
Collapse
Affiliation(s)
- Florian Brugger
- Movement Disorders Center of Eastern Switzerland Department of Neurology Kantonsspital St.Gallen St.Gallen Switzerland
| | - Michael Schüpbach
- Movement Disorders Center Department of Neurology University Hospital Berne University of Berne Berne Switzerland
| | - Michel Koenig
- Laboratoire de Diagnostic Génétique Nouvel Hôpital Civil Strasbourg France
- Institut de Génétique et de Biologie Moléculaire et Cellulaire CNRS/Université de Strasbourg/INSERM Illkirch France
| | - René Müri
- Perception and Eye Movement Laboratory Departments of Neurology and Clinical Research Inselspital, University Hospital Berne Berne Switzerland
| | - Stephan Bohlhalter
- Perception and Eye Movement Laboratory Departments of Neurology and Clinical Research Inselspital, University Hospital Berne Berne Switzerland
- Neurology and Neurorehabilitation Center Department of Internal Medicine Luzerner Kantonsspital Lucerne Switzerland
| | - Alain Kaelin-Lang
- Movement Disorders Center Department of Neurology University Hospital Berne University of Berne Berne Switzerland
| | - Christian P Kamm
- Perception and Eye Movement Laboratory Departments of Neurology and Clinical Research Inselspital, University Hospital Berne Berne Switzerland
| | - Georg Kägi
- Movement Disorders Center of Eastern Switzerland Department of Neurology Kantonsspital St.Gallen St.Gallen Switzerland
| |
Collapse
|
46
|
Pollo C, Kaelin-Lang A, Oertel MF, Stieglitz L, Taub E, Fuhr P, Lozano AM, Raabe A, Schüpbach M. Directional deep brain stimulation: an intraoperative double-blind pilot study. Brain 2014; 137:2015-26. [DOI: 10.1093/brain/awu102] [Citation(s) in RCA: 238] [Impact Index Per Article: 23.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
47
|
Vanbellingen T, Bertschi M, Nyffeler T, Cazzoli D, Wiest R, Bassetti C, Kaelin-Lang A, Müri R, Bohlhalter S. Left posterior parietal theta burst stimulation affects gestural imitation regardless of semantic content. Clin Neurophysiol 2014; 125:457-62. [DOI: 10.1016/j.clinph.2013.07.024] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2013] [Revised: 07/10/2013] [Accepted: 07/22/2013] [Indexed: 11/27/2022]
|
48
|
Meier B, Weiermann B, Gutbrod K, Stephan MA, Cock J, Müri RM, Kaelin-Lang A. Implicit task sequence learning in patients with Parkinson's disease, frontal lesions and amnesia: The critical role of fronto–striatal loops. Neuropsychologia 2013. [DOI: 10.1016/j.neuropsychologia.2013.10.009] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
49
|
Meier B, Weiermann B, Gutbrod K, Stephan MA, Cock J, Mür RM, Kaelin-Lang A. Implicit task sequence learning in patients with Parkinson's disease, frontal lesions and amnesia: the critical role of fronto–striatal loops. Neuropsychologia 2013; 51:3014-3024. [PMID: 24436969] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
The purpose of this study was to investigate the role of the fronto–striatal system for implicit task sequence learning. We tested performance of patients with compromised functioning of the fronto–striatal loops, that is, patients with Parkinson's disease and patients with lesions in the ventromedial or dorsolateral prefrontal cortex. We also tested amnesic patients with lesions either to the basal forebrain/orbitofrontal cortex or to thalamic/medio-temporal regions. We used a task sequence learning paradigm involving the presentation of a sequence of categorical binary-choice decision tasks. After several blocks of training, the sequence, hidden in the order of tasks, was replaced by a pseudo-random sequence. Learning (i.e., sensitivity to the ordering) was assessed by measuring whether this change disrupted performance. Although all the patients were able to perform the decision tasks quite easily, those with lesions to the fronto–striatal loops (i.e., patients with Parkinson's disease, with lesions in the ventromedial or dorsolateral prefrontal cortex and those amnesic patients with lesions to the basal forebrain/orbitofrontal cortex) did not show any evidence of implicit task sequence learning. In contrast, those amnesic patients with lesions to thalamic/medio-temporal regions showed intact sequence learning. Together, these results indicate that the integrity of the fronto–striatal system is a prerequisite for implicit task sequence learning.
Collapse
|
50
|
Pollo C, Stieglitz L, Oertel M, Kaelin-Lang A, Schüpbach M. Improved intraoperative therapeutic window with directional DBS compared to omnidirectional DBS using a novel lead design. J Neurol Sci 2013. [DOI: 10.1016/j.jns.2013.07.552] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|